

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 18 of 18 returned.**☐ 1. Document ID: US 6464986 B1

L4: Entry 1 of 18

File: USPT

Oct 15, 2002

DOCUMENT-IDENTIFIER: US 6464986 B1

TITLE: Method for treating pain by peripheral administration of a neurotoxin

Brief Summary Text (80):

"Targeting moiety" means a molecule that has a specific binding affinity for a cell surface receptor. The targeting moiety is not a Clostridial neurotoxin H.sub.C, or peptides derived from H.sub.c with at least one of its amino acid deleted, modified or replaced. The targeting moiety is a molecule which is not a Clostridial neurotoxin, for example can be a bradykinin.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 2. Document ID: US 6461617 B1

L4: Entry 2 of 18

File: USPT

Oct 8, 2002

DOCUMENT-IDENTIFIER: US 6461617 B1

TITLE: Recombinant toxin fragments

Brief Summary Text (5):

The clostridia neurotoxins share a common architecture of a catalytic L-chain (LC, ca 50 kDa) disulphide linked to a receptor binding and translocating H-chain (HC, ca 100 kDa). The HC polypeptide is considered to comprise all or part of two distinct functional domains. The carboxy-terminal half of the HC (ca 50 kDa), termed the H.sub.C domain, is involved in the high affinity, neurospecific binding of the neurotoxin to cell surface receptors on the target neuron, whilst the amino-terminal half, termed the H.sub.N domain (ca 50 kDa), is considered to mediate the translocation of at least some portion of the neurotoxin across cellular

membranes such that the functional activity of the LC is expressed within the target cell. The H.sub.N domain also has the property, under conditions of low pH, of forming ion-permeable channels in lipid membranes, this may in some manner relate to its translocation function.

Brief Summary Text (9):

(B) Clostridial Neurotoxin Heavy Chain H.sub.N Domain: a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell. the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell. the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH. the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.

Brief Summary Text (10):

(C) Clostridial Neurotoxin Heavy Chain H.sub.C Domain. a portion of the heavy chain which is responsible for binding of the native holotoxin to cell surface receptor(s) involved in the intoxicating action of clostridial toxin prior to internalisation of the toxin into the cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 3. Document ID: US 6444209 B1

L4: Entry 3 of 18

File: USPT

Sep 3, 2002

DOCUMENT-IDENTIFIER: US 6444209 B1

TITLE: Hybrid botulin neurotoxins

Brief Summary Text (26):

In a separate embodiment of the method, hybrid genes contain the translocation domain of the heavy chain from one serotype, receptor binding domain of the heavy chain from another serotype, combined with the light chain of a third C. botulinum serotype. Thus, it is possible to construct a variety of new toxin molecules by combining any of the three functional domains from any C. botulinum neurotoxin serotypes.

Detailed Description Text (19):

In one embodiment, one may manipulate the neurotoxin gene sequences to combine functional domains from different serotypes in a novel gene. For example, the gene segment coding the catalytic light chain of a type A neurotoxin, the gene segment coding the channel forming domain of a type B neurotoxin and the gene segment coding the receptor-binding domain of a type E neurotoxin may be joined together by genetic engineering techniques, and hybrid neurotoxin expressed in the recombinant microorganism.

Detailed Description Text (64):

Using recombinant DNA technology, it is also possible to construct hybrid toxins containing not only the light

chain from one *C. botulinum* serotype and the heavy chain from another, but also hybrid genes which contain the translocation domain of the heavy chain from one serotype, receptor binding domain of the heavy chain from another serotype, combined with the light chain of a third *C. botulinum* serotype. Thus, it is possible to construct a variety of new toxin molecules by combining any of the three functional domains from any *C. botulinum* neurotoxin serotypes.

Detailed Description Text (68):

Several laboratories have cloned different clostridial neurotoxins genes or gene domains. *C. tetanus* neurotoxin (TeNT) receptor binding domain (about 1.4 kbp) has been expressed in *E. coli* (Fairweather, N. F., et al., *J. Bacteriol.* 165:21-27, 1986; Fairweather, N. F., et al., *FEBS Lett.* 323:218-222, 1993; Makoff, A. J., et al., *Biotechnology* 7:1043-1046, 1989a; Figueiredo, D., et al., *Inf. Immun.* 63:3218-3221, 1995), *Saccharomyces cerevisiae* (Romanos, M. A., et al., *Nucl. Acids Res.* 19:1461-1467, 1991) *Pichia pastoris* (Clare, J. J., et al., *Biotechnology* 7:455-460, 1991) *Lactococcus lactis* (Wells, J. M., et al., *Mol. Microbiol.* 8:1156-1162, 1993) and a baculovirus system (Charles, I. G., et al., *Inf. Immun.* 59:1627-1632, 1991). BoNT/A receptor binding domain (about 1.3 kbp) has been expressed in *E. coli* as well (Clayton, M. C., et al., *Inf. Immunol.* 63:2738-2742, 1995; Middlebrook, J. L. and Brown, J. E., *Curr. Top. Microbiol. Immun.* 195:89-122, 1995).

Detailed Description Text (80):

The subfragments of the BoNT/A gene encoding the entire light chain (nucleotides 1-1344), the entire heavy chain (nucleotides 1345-3891), channel forming (nucleotides 1345-2687) and receptor binding (nucleotides 2581-3891) domains or their truncated fragments (nucleotides 1345-1789; 1345-2083; 1345-2416; 3301-3891) of the heavy chain were cloned. This was accomplished via the polymerase chain reaction using specific oligonucleotides and *C. botulinum* chromosomal DNA as a template.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 4. Document ID: US 6372226 B2

L4: Entry 4 of 18

File: USPT

Apr 16, 2002

DOCUMENT-IDENTIFIER: US 6372226 B2

TITLE: Intraspinal botulinum toxin for treating pain

Detailed Description Text (18):

As set forth above, we have discovered that a surprisingly effective and long lasting treatment of pain can be achieved by intraspinal administration of a neurotoxin to an afflicted patient. In its most preferred embodiment, the present invention is practiced by intrathecal injection of botulinum toxin type A. Significantly, we have discovered that dramatic, long term analgesic and/or improved patient function effects can be achieved through intraspinal administration of a neurotoxin by the methods disclosed herein even though the neurotoxin has not had attached or fused to it, by various manipulative techniques or technologies, a neuronal targeting moiety, such as a non-neurotoxin protein, to provide targeting specificity of the

neurotoxin for one or more particular types of neurons. Thus, the present invention excludes from its scope the use of any neurotoxins with one or more artificially attached or fused neuronal targeting moieties. A neurotoxin can display a natural binding affinity for a neuron (i.e. for a particular receptor on the surface of the neuron) due to the presence of a binding moiety inherent to the structure of the native neurotoxin molecule (for example, the binding domain of the heavy chain of a botulinum toxin, i.e. the H.sub.c fragment). Thus, for clarity "targeting moiety" or "neuronal targeting moiety" as used herein means a targeting moiety which provides to a neurotoxin specific or enhanced neuronal binding affinity and which is not a natural or inherent feature of the neurotoxin which has such a targeting moiety. Contrarily, "binding moiety" as used herein means the inherent component or domain of the native neurotoxin which provides neuronal binding affinity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 5. Document ID: US 6333037 B1

L4: Entry 5 of 18

File: USPT

Dec 25, 2001

DOCUMENT-IDENTIFIER: US 6333037 B1

TITLE: Methods for treating pain with a modified neurotoxin

Detailed Description Text (18):

As set forth above, we have discovered that a surprisingly effective and long lasting treatment of pain can be achieved by intraspinal administration of a neurotoxin to an afflicted patient. In its most preferred embodiment, the present invention is practiced by intrathecal injection of botulinum toxin type A. Significantly, we have discovered that dramatic, long term analgesic and/or improved patient function effects can be achieved through intraspinal administration of a neurotoxin by the methods disclosed herein even though the neurotoxin has not had attached or fused to it, by various manipulative techniques or technologies, a neuronal targeting moiety, such as a non-neurotoxin protein, to provide targeting specificity of the neurotoxin for one or more particular types of neurons. Thus, the present invention excludes from its scope the use of any neurotoxins with one or more artificially attached or fused neuronal targeting moieties. A neurotoxin can display a natural binding affinity for a neuron (i.e. for a particular receptor on the surface of the neuron) due to the presence of a binding moiety inherent to the structure of the native neurotoxin molecule (for example, the binding domain of the heavy chain of a botulinum toxin, i.e. the H.sub.c fragment). Thus, for clarity "targeting moiety" or "neuronal targeting moiety" as used herein means a targeting moiety which provides to a neurotoxin specific or enhanced neuronal binding affinity and which is not a natural or inherent feature of the neurotoxin which has such a targeting moiety. Contrarily, "binding moiety" as used herein means the inherent component or domain of the native neurotoxin which provides neuronal binding affinity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 6. Document ID: US 6312708 B1

L4: Entry 6 of 18

File: USPT

Nov 6, 2001

DOCUMENT-IDENTIFIER: US 6312708 B1

TITLE: Botulinum toxin implant

Brief Summary Text (67):

The tetanus toxin bears many similarities to the botulinum toxins. Thus, both the tetanus toxin and the botulinum toxins are polypeptides made by closely related species of Clostridium (Clostridium tetani and Clostridium botulinum, respectively). Additionally, both the tetanus toxin and the botulinum toxins are dichain proteins composed of a light chain (molecular weight about 50 kD) covalently bound by a single disulfide bond to a heavy chain (molecular weight about 100 kD). Hence, the molecular weight of tetanus toxin and of each of the seven botulinum toxins (non-complexed) is about 150 kD. Furthermore, for both the tetanus toxin and the botulinum toxins, the light chain bears the domain which exhibits intracellular biological (protease) activity, while the heavy chain comprises the receptor binding (immunogenic) and cell membrane translocational domains.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KMOC	Draw Desc
------	-----------

☐ 7. Document ID: US 6268159 B1

L4: Entry 7 of 18

File: USPT

Jul 31, 2001

DOCUMENT-IDENTIFIER: US 6268159 B1

TITLE: Imaging of colorectal cancer using ST receptor binding compounds

Brief Summary Text (97):

Toxins are useful as active moieties. When a toxin is conjugated to an ST receptor binding moiety, the conjugated composition is specifically delivered to a metastasized colorectal cell by way of the ST receptor binding moiety and the toxin moiety kills the cell. Toxins are generally complex toxic products of various organisms including bacteria, plants, etc. Examples of toxins include but are not limited to: ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin. As discussed above, when protein toxins are employed with ST receptor binding peptides, conjugated compositions may be produced using recombinant DNA techniques. Briefly, a recombinant DNA molecule can be constructed which encodes

both the ST receptor ligand and the toxin on a chimeric gene. When the chimeric gene is expressed, a fusion protein is produced which includes an ST receptor binding moiety and an active moiety. Protein toxins are also useful to form conjugated compounds with ST receptor binding peptides through non-peptidyl bonds.

Brief Summary Text (126):

One aspect of the present invention relates to a method of treating individuals suspected of suffering from metastasized colorectal cancer. Such individuals may be treated by administering to the individual a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is a peptide. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ

ID NO:54 and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a radiostable conjugated compound described in Example 1. The individual being treated may be diagnosed as having metastasized colorectal cancer or may be diagnosed as having localized colorectal cancer and may undergo the treatment proactively in the event that there is some metastasis as yet undetected. The pharmaceutical composition contains a therapeutically effective amount of the conjugated composition. A therapeutically effective amount is an amount which is effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc
------	-----------

Image

☐ 8. Document ID: US 6235289 B1

L4: Entry 8 of 18

File: USPT

May 22, 2001

DOCUMENT-IDENTIFIER: US 6235289 B1

TITLE: Intraspinal methods for treating pain

Drawing Description Text (27):

As set forth above, we have discovered that a surprisingly effective and long lasting treatment of pain can be achieved by intraspinal administration of a neurotoxin to an afflicted patient. In its most preferred embodiment, the present invention is practiced by intrathecal injection of botulinum toxin type A. Significantly, we have discovered that dramatic, long term analgesic and/or improved patient function effects can be achieved through intraspinal administration of a neurotoxin by the methods disclosed herein even though the neurotoxin has not had attached or fused to it, by various manipulative techniques or technologies, a neuronal targeting moiety, such as a non-neurotoxin protein, to provide targeting specificity of the neurotoxin for one or more particular types of neurons. Thus, the present invention excludes from its scope the use of any neurotoxins with one or more artificially attached or fused neuronal targeting moieties. A neurotoxin can display a natural binding affinity for a neuron (i.e. for a particular receptor on the surface of the neuron) due to the presence of a binding moiety inherent to the structure of the native neurotoxin molecule (for example, the binding domain of the heavy chain of a botulinum toxin, i.e. the H_{sup}C fragment). Thus, for clarity "targeting moiety" or "neuronal targeting moiety" as used herein means a targeting moiety which provides to a neurotoxin specific or enhanced neuronal binding affinity and which is not a natural or inherent feature of the neurotoxin which has such a targeting moiety. Contrarily, "binding moiety" as used herein means the inherent component or domain of the native neurotoxin which provides neuronal binding affinity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc
------	-----------

Image

☐ 9. Document ID: US 6203794 B1

L4: Entry 9 of 18

File: USPT

Mar 20, 2001

DOCUMENT-IDENTIFIER: US 6203794 B1

TITLE: Modification of clostridial toxins for use as transport proteins

Brief Summary Text (4):

Tetanus toxin (TeTx) and botulinum toxin (BoNT) are potent neurotoxins that induce paralysis by mechanisms that involve the inhibition of neurotransmitter release. These Clostridial neurotoxins are initially produced as single-chain proteins of .about.150 kDa. Proteolytic cleavage then generates an active dichain molecule having a .about.100 kDa heavy (H) and a .about.50 kDa light (L) chain that are linked by a single interchain disulfide bond. The H chain contains domains which contribute to the binding of the toxin to neuronal cell surface receptors and which facilitate translocation of the L chain into cells. The L chain is responsible for blocking neurotransmitter release.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 10. Document ID: US 6187536 B1

L4: Entry 10 of 18

File: USPT

Feb 13, 2001

DOCUMENT-IDENTIFIER: US 6187536 B1

TITLE: Methods of identifying and detecting pancreatic cancer

Brief Summary Text (82):

One aspect of the present invention relates to a method of treating individuals who have pancreatic cancer. Such individuals may be treated by administering to the individual a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises a CCK A receptor specific binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises a CCK A receptor specific binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the CCK A receptor specific binding moiety is an antibody. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises a CCK A receptor specific binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the CCK A receptor specific binding moiety. The CCK A receptor binding moiety

may be a monoclonal antibodies, humanized antibodies, chimeric antibodies, primatized antibodies as well as humanized Fab fragments, humanized F(Ab)₂ fragments, chimeric Fab fragments, chimeric F(Ab)₂ Primatized fragments Fab fragments, primatized F(Ab)₂ fragments. In some embodiments of the present invention, the CCK A receptor specific binding moiety is asperlicin or L-364,718/MK-329. In some embodiments of the present, the active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

□ 11. Document ID: US 6113915 A

L4: Entry 11 of 18

File: USPT

Sep 5, 2000

DOCUMENT-IDENTIFIER: US 6113915 A

TITLE: Methods for treating pain

Detailed Description Text (19):

As set forth above, we have discovered that a surprisingly effective and long lasting treatment of pain can be achieved by intraspinal administration of a neurotoxin to an afflicted patient. In its most preferred embodiment, the present invention is practiced by intrathecal injection of botulinum toxin type A. Significantly, we have discovered that dramatic, long term analgesic and/or improved patient function effects can be achieved through intraspinal administration of a neurotoxin by the methods disclosed herein even though the neurotoxin has not had attached or fused to it, by various manipulative techniques or technologies, a neuronal targeting moiety, such as a non-neurotoxin protein, to provide targeting specificity of the neurotoxin for one or more particular types of neurons. Thus, the present invention excludes from its scope the use of any neurotoxins with one or more artificially attached or fused neuronal targeting moieties. A neurotoxin can display a natural binding affinity for a neuron (i.e. for a particular receptor on the surface of the neuron) due to the presence of a binding moiety inherent to the structure of the native neurotoxin molecule (for example, the binding domain of the heavy chain of a botulinum toxin, i.e. the H.sub.C fragment). Thus, for clarity "targeting moiety" or "neuronal targeting moiety" as used herein means a targeting moiety which provides to a neurotoxin specific or enhanced neuronal binding affinity and which is not a natural or inherent feature of the neurotoxin which has such a targeting moiety. Contrarily, "binding moiety" as used herein means the inherent component or domain of the native neurotoxin which provides neuronal binding affinity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 12. Document ID: US 6080400 A

L4: Entry 12 of 18

File: USPT

Jun 27, 2000

DOCUMENT-IDENTIFIER: US 6080400 A

TITLE: Compositions for the prevention and treatment of verotoxin-induced disease

Detailed Description Text (42):

Fusion proteins comprising the receptor binding domain (i.e., the B subunit) of botulinal toxins may include amino acid residues located beyond the termini of the domains defined above.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 13. Document ID: US 6060037 A

L4: Entry 13 of 18

File: USPT

May 9, 2000

DOCUMENT-IDENTIFIER: US 6060037 A

TITLE: Compositions that specifically bind to colorectal cancer cells and methods of using the same

Detailed Description Text (86):

Toxins are useful as active moieties. When a toxin is conjugated to an ST receptor binding moiety, the conjugated composition is specifically delivered to a metastasized colorectal cell by way of the ST receptor binding moiety and the toxin moiety kills the cell. Toxins are generally complex toxic products of various organisms including bacteria, plants, etc. Examples of toxins include but are not limited to: ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin. As discussed above, when protein toxins are employed with ST receptor binding peptides, conjugated compositions may be produced using recombinant DNA techniques. Briefly, a recombinant DNA molecule can be constructed which encodes both the ST receptor ligand and the toxin on a chimeric gene. When the chimeric gene is expressed, a fusion protein is produced which includes an ST receptor binding moiety and an active moiety. Protein toxins are also useful to form conjugated compounds with ST receptor binding peptides through non-peptidyl bonds.

Detailed Description Text (116):

One aspect of the present invention relates to a method of treating individuals suspected of suffering from metastasized colorectal cancer. Such individuals may be treated by administering to the individual a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is a peptide. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54 and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A. chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent

and a radiostable conjugated compound described in Example 1. The individual being treated may be diagnosed as having metastasized colorectal cancer or may be diagnosed as having localized colorectal cancer and may undergo the treatment proactively in the event that there is some metastasis as yet undetected. The pharmaceutical composition contains a therapeutically effective amount of the conjugated composition. A therapeutically effective amount is an amount which is effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 14. Document ID: US 6051239 A

L4: Entry 14 of 18

File: USPT

Apr 18, 2000

DOCUMENT-IDENTIFIER: US 6051239 A

TITLE: Compositions and methods for systemic delivery of oral vaccines and therapeutic agents

Detailed Description Text (3):

The present invention provides a modified botulinum toxin which can be used as an oral delivery vehicle for antigenic peptides including, but not limited to, botulinum toxin and other therapeutic agents to the general circulation. It has now been found that botulinum toxin translocates from the gut to the general circulation by binding to serospecific receptors on the mucosal side of polarized gut cells grown in a monolayer. Bound toxin is actively transported across the cells and delivered intact and unmodified on the serosal side of the monolayers. It has been suggested that auxiliary proteins such as hemagglutinin, which is a component of the non-covalent complex of proteins including the botulinum toxin which is released by Clostridium, may mediate binding and transport of the toxin across the gut wall. However, experiments performed with a recombinant form of the holotoxin now demonstrate that the botulinum toxin itself possesses the binding domain that recognizes receptors on the surface of gut cells. Further, it has now been demonstrated that modifications can be made to the light chain of the toxin to render it nontoxic without altering the capability of the protein to translocate from the gut to the general circulation. Accordingly, for the purposes of the present invention, by "modified botulinum toxin" is meant a botulinum toxin which maintains its capability of translocating from the gut to the general circulation but which is nontoxic. Alterations which will render the botulinum toxin nontoxic include mutations to the amino acid sequence of the light chain and deletion of the light chain or portions thereof. In a preferred embodiment, mutations are made to the zinc binding motif or the substrate binding motif of the light chain. For the purposes of this invention, by "nontoxic" it is meant that exposure of the cholinergic nerve endings to the modified botulinum toxin does not result in blockade of transmitter release in the nerve endings and paralysis. The effects of alterations rendering the botulinum toxin nontoxic on the ability of the toxin to translocate from the gut to the general circulation can be routinely performed in accordance with the teachings provided herein so that one of skill may identify modified botulinum toxins of the present invention. Included within this definition of modified botulinum toxins are botulinum toxins which further comprise a selected antigen for a protein other than botulinum toxin or a therapeutic agent.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KIMC	Dram. Desc
------	------------

☐ 15. Document ID: US 5939070 A

L4: Entry 15 of 18

File: USPT

Aug 17, 1999

DOCUMENT-IDENTIFIER: US 5939070 A

TITLE: Hybrid botulinal neurotoxins

Brief Summary Text (24):

In a separate embodiment of the method, hybrid genes contain the translocation domain of the heavy chain from one serotype, receptor binding domain of the heavy chain from another serotype, combined with the light chain of a third *C. botulinum* serotype. Thus, it is possible to construct a variety of new toxin molecules by combining any of the three functional domains from any *C. botulinum* neurotoxin serotypes.

Detailed Description Text (16):

In one embodiment, one may manipulate the neurotoxin gene sequences to combine functional domains from different serotypes in a novel gene. For example, the gene segment coding the catalytic light chain of a type A neurotoxin, the gene segment coding the channel forming domain of a type B neurotoxin and the gene segment coding the receptor-binding domain of a type E neurotoxin may be joined together by genetic engineering techniques, and hybrid neurotoxin expressed in the recombinant microorganism.

Detailed Description Text (47):

Using recombinant DNA technology, it is also possible to construct hybrid toxins containing not only the light chain from one *C. botulinum* serotype and the heavy chain from another, but also hybrid genes which contain the translocation domain of the heavy chain from one serotype, receptor binding domain of the heavy chain from another serotype, combined with the light chain of a third *C. botulinum* serotype. Thus, it is possible to construct a variety of new toxin molecules by combining any of the three functional domains from any *C. botulinum* neurotoxin serotypes.

Detailed Description Text (51):

Several laboratories have cloned different clostridial neurotoxins genes or gene domains. *C. tetanus* neurotoxin (TeNT) receptor binding domain (about 1.4 kbp) has been expressed in *E. coli* (Fairweather, N. F., et al., *J. Bacteriol.* 165:21-27, 1986; Fairweather, N. F., et al., *FEBS Lett.* 323:218-222, 1993; Makoff, A. J., et al., *Biotechnology* 7:1043-1046, 1989a; Figueiredo, D., et al., *Inf. Immun.* 63:3218-3221, 1995), *Saccharomyces cerevisiae* (Romanos, M. A., et al., *Nucl. Acids Res.* 19:1461-1467, 1991) *Pichia pastoris* (Clare, J. J., et al., *Biotechnology* 7:455-460, 1991) *Lactococcus lactis* (Wells, J. M., et al., *Mol. Microbiol.* 8:1156-1162, 1993) and a baculovirus system (Charles, I. G., et al., *Inf. Immun.* 59:1627-1632, 1991). BoNT/A receptor binding domain (about 1.3 kbp) has been expressed in *E. coli* as well (Clayton, M. C., et al., *Inf. Immunol.* 63:2738-2742, 1995; Middlebrook, J. L. and Brown, J. E., *Curr. Top. Microbiol. Immun.* 195:89-122, 1995).

Detailed Description Text (63):

The subfragments of the BoNT/A gene encoding the entire light chain (nucleotides 1-1344), the entire heavy chain (nucleotides 1345-3891), channel forming (nucleotides 1345-2687) and receptor binding (nucleotides 2581-3891) domains or their truncated fragments (nucleotides 1345-1789; 1345-2083; 1345-2416; 3301-3891) of the heavy chain were cloned. This was accomplished via the polymerase chain reaction using specific oligonucleotides and of C. botulinum chromosomal DNA as a template.

CLAIMS:

5. A hybrid botulinal neurotoxin comprising light and heavy chains, which comprise botulinal neurotoxin catalytic, channel forming and receptor binding functional domains, wherein at least two functional domains are from botulinal neurotoxins of different serotypes and wherein the light and heavy chains are linked by a heterobifunctional thiol/amine linker and wherein the specific toxicity of the neurotoxin is at least 10^{sup.6} LD_{sub.50} /mg protein in vivo.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw. Desc
------	------------

☐ 16. Document ID: US 5879656 A

L4: Entry 16 of 18

File: USPT

Mar 9, 1999

DOCUMENT-IDENTIFIER: US 5879656 A

TITLE: Methods of treating metastatic colorectal cancer with ST receptor binding compounds

Detailed Description Text (81):

Toxins are useful as active moieties. When a toxin is conjugated to an ST receptor binding moiety, the conjugated composition is specifically delivered to a metastasized colorectal cell by way of the ST receptor binding moiety and the toxin moiety kills the cell. Toxins are generally complex toxic products of various organisms including bacteria, plants, etc. Examples of toxins include but are not limited to: ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin. As discussed above, when protein toxins are employed with ST receptor binding peptides, conjugated compositions may be produced using recombinant DNA techniques. Briefly, a recombinant DNA molecule can be constructed which encodes both the ST receptor ligand and the toxin on a chimeric gene. When the chimeric gene is expressed, a fusion protein is produced which includes an ST receptor binding moiety and an active moiety. Protein toxins are also useful to form conjugated compounds with ST receptor binding peptides through non-peptidyl bonds.

Detailed Description Text (110):

One aspect of the present invention relates to a method of treating individuals suspected of suffering from metastasized colorectal cancer. Such individuals may be treated by administering to the individual a

pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is a peptide. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56, and fragments and derivatives thereof and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54 and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, Pseudomonas exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a radiostable conjugated compound described in Example 1. The individual being treated may be diagnosed as having metastasized colorectal cancer or may be diagnosed as having localized colorectal cancer and may undergo the treatment proactively in the event that there is some metastasis as yet undetected. The

pharmaceutical composition contains a therapeutically effective amount of the conjugated composition. A therapeutically effective amount is an amount which is effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw	Desc
------	------	------

☐ 17. Document ID: US 5695956 A

L4: Entry 17 of 18

File: USPT

Dec 9, 1997

DOCUMENT-IDENTIFIER: US 5695956 A

TITLE: Clostridium perfringens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent

Detailed Description Text (2):

The present invention has met the hereinbefore described need. The present invention provides a recombinant DNA plasmid or bacteriophage transfer vector having an Escherichia coli expression vector and a DNA sequence encoding for a Clostridium perfringens type A enterotoxin gene fragment that produces a Clostridium perfringens type A enterotoxin receptor binding domain. The present invention provides a toxoid produced by a recombinant plasmid in an Escherichia coli strain. This plasmid contains a Clostridium perfringens type A enterotoxin gene fragment encoding amino acids 171 through 319 that constitutes the toxoid. This plasmid contains the Escherichia coli expression vector regulatory regions and the Clostridium perfringens type A enterotoxin gene fragment and is capable of producing a toxoid. This plasmid is designated pPH300. The toxoid of this invention recognizes, irreversibly binds to and saturates receptor sites on intestinal membranes and thus effectually competes for those sites with Clostridium perfringens type A enterotoxin. The toxoid of this invention is nontoxic to mammalian cells. This toxoid may be used as a vaccine for preventing the symptoms associated with food poisoning in patients due to Clostridium perfringens type A enterotoxin. The toxoid of this invention may be used to provide a treatment for the symptoms associated with food poisoning in patients due to Clostridium perfringens type A enterotoxin.

Detailed Description Text (14):

It is a further object of this invention to demonstrate that the 30 carboxy-terminal terminal amino acids of Clostridium perfringens type A enterotoxin are sufficient for recognizing and irreversibly binding to the Clostridium perfringens type A enterotoxin receptor, and thus define these 30 carboxy-terminal amino acids as a functional receptor-binding domain.

Detailed Description Text (25):

When the .lambda.gtII library of Clostridium perfringens DNA was screened with anti-Clostridium perfringens type A enterotoxin MAb3C9, one positive-scoring plaque was obtained and named lambda ph161 (.lambda.ph161). The construction of the .lambda.gtII library and the resultant .lambda.ph161 is set forth in FIG. 1. Since it is known that MAb3C9 recognizes an epitope which appears to be at or near the receptor-binding domain of Clostridium perfringens type A enterotoxin, this suggests that the positive scoring plaque .lambda.ph161

contains a Clostridium perfringens type A enterotoxin gene insert that encodes a Clostridium perfringens type A enterotoxin receptor-binding domain. Lambda ph161 was isolated and used to generate a temperature sensitive (t.sup.s) lysogen in Escherichia coli Y1089 for phage storage.

Other Reference Publication (1):

"The 31 C-Term Amino Acids of Clostridium perfringens Enterotoxin Defines e Receptor Binding Domain", poster displayed at Annual Meeting of American Society for Microbiology, Anaheim, California (May 1990), P. C. Hanna and B. A. McClane Abstract.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 18. Document ID: US 5518888 A

L4: Entry 18 of 18

File: USPT

May 21, 1996

DOCUMENT-IDENTIFIER: US 5518888 A

TITLE: ST receptor binding compounds and methods of using the same

Brief Summary Text (97):

Toxins are useful as active moieties. When a toxin is conjugated to an ST receptor binding moiety, the conjugated composition is specifically delivered to a metastasized colorectal cell by way of the ST receptor binding moiety and the toxin moiety kills the cell. Toxins are generally complex toxic products of various organisms including bacteria, plants, etc. Examples of toxins include but are not limited to: ricin, ricin A chain (ricin toxin), Pseudomonas exotoxin (PE), diphtheria toxin (DT), Clostridium perfringens phospholipase C (PLC), bovine pancreatic ribonuclease (BPR), pokeweed antiviral protein (PAP), abrin, abrin A chain (abrin toxin), cobra venom factor (CVF), gelonin (GEL), saporin (SAP), modeccin, viscumin and volkensin. As discussed above, when protein toxins are employed with ST receptor binding peptides, conjugated compositions may be produced using recombinant DNA techniques. Briefly, a recombinant DNA molecule can be constructed which encodes both the ST receptor ligand and the toxin on a chimeric gene. When the chimeric gene is expressed, a fusion protein is produced which includes an ST receptor binding moiety and an active moiety. Protein toxins are also useful to form conjugated compounds with ST receptor binding peptides through non-peptidyl bonds.

Brief Summary Text (126):

One aspect of the present invention relates to a method of treating individuals suspected of suffering from metastasized colorectal cancer. Such individuals may be treated by administering to the individual a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is a peptide. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that

comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent and the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable therapeutic agent. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium* perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives thereof and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium* perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, *Pseudomonas* exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a conjugated compound that comprises an ST receptor binding moiety and an active moiety wherein the ST receptor binding moiety is selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54 and the active moiety is a radiostable active agent selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, cis-platin, vindesine, mitomycin and bleomycin, alkaline phosphatase, ricin A chain, *Pseudomonas* exotoxin and diphtheria toxin. In some embodiments of the present invention, the pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent and a radiostable conjugated compound described in Example 1. The individual being treated may be diagnosed as having metastasized colorectal cancer or may be diagnosed as having localized colorectal cancer and may undergo the treatment proactively in the event that there is some metastasis as yet undetected. The pharmaceutical composition contains a therapeutically effective amount of the conjugated composition. A therapeutically effective amount is an amount which is effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc
------	-----------

Image

Generate Collection Print

Terms	Documents
L3 same (clostrid\$ or botul\$ or neurotox\$)	18

Display Format: KWIC Change Format

[Previous Page](#) [Next Page](#)

WEST

Generate Collection

Print

L10: Entry 52 of 105

File: USPT

May 16, 2000

US-PAT-NO: 6063768

DOCUMENT-IDENTIFIER: US 6063768 A

TITLE: Application of botulinum toxin to the management of neurogenic inflammatory disorders

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
First; Eric R.	South Boston	MA	02127	

US-CL-CURRENT: 514/14; 424/282.1, 424/810, 435/842, 514/2, 514/825, 514/885

CLAIMS:

I claim:

1. A method for treating neurogenic inflammation comprising, administering a therapeutically effective amount of Clostridium botulinum toxin to antagonize the action of at least one neurogenic inflammatory mediator, whereby said toxin interrupts a neurogenic pathway associated with said neurogenic inflammation.
2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin A, B, C, D, E, F and G.
3. The method of claim 1, further comprising treating the neurogenic inflammation by inhibiting at least one neurogenic inflammatory mediator selected from the group consisting of substance-P (SP), calcitonin gene-related peptide (cGRP), vasoactive intestinal peptide (VIP), interleukin-1 (IL-1), interleukin-2 (IL-2), nitric oxide (NO), 5-hydroxytryptamine (5-HT), tumor necrosis factor (TNF), and nerve growth factor (NGF).
4. The method of claim 1, wherein the botulinum toxin is less than about, or equal to 1000 U.
5. The method of claim 1, wherein the neurogenic inflammation is caused by rheumatoid arthritis.
6. The method of claim 1, wherein the neurogenic inflammation is caused by gout.

1. Dasgupta,Bivash R., Tee,Shang-You., Crocker,John C., Frisken,B J., Weitz,D A.
Microrheology of polyethylene oxide using diffusing wave spectroscopy and single scattering.
(2002) *Phys Rev E Stat Nonlin Soft Matter Phys* **65** (5 Pt 1):051505
MedlineID: 22055577 PubMedID: 12059562
2. Dasgupta,B R., Rothstein,E., Boroff,D A.
Method for quantitative determination of free and peptide-linked tryptophan after reaction with 2-hydroxy-5-nitrobenzyl bromide.
(1965) *Anal Biochem* **11** (3):555-65
MedlineID: 66075052 PubMedID: 5856610
3. Dasgupta,B R., Boroff,D A., Rothstein,E.
Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A.
(1966) *Biochem Biophys Res Commun* **22** (6):750-6
MedlineID: 66167378 PubMedID: 5329438
4. Boroff,D A., Townend,R., Fleck,U., DasGupta,B R.
Ultracentrifugal analysis of the crystalline toxin and isolated fractions of Clostridium botulinum type A.
(1966) *J Biol Chem* **241** (22):5165-7
MedlineID: 67052756 PubMedID: 4959143
5. DasGupta,B R., Boroff,D A.
Interference in nitrosonaphthol method of tyrosine assay due to chloride.
(1966) *Anal Biochem* **15** (1):194-9
MedlineID: 67095148 PubMedID: 5959427
6. Boroff,D A., Dasgupta,B R.
Study of the toxin of Clostridium botulinum. Effects of 2-hydroxy-5-nitrobenzyl bromide on the biological activity of botulinum toxin.
(1966) *Biochim Biophys Acta* **117** (2):289-96
MedlineID: 67120734 PubMedID: 5335812
7. DasGupta,B R., Boroff,D A.

Chromatographic isolation of hemagglutinin-free neurotoxin from crystalline toxin of Clostridium botulinum type A.

(1967) *Biochim Biophys Acta* **147** (3):603-5

MedlineID: 68133343 PubMedID: 4866586

8. DasGupta,B R., Boroff,D A.

Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration.

(1968) *J Biol Chem* **243** (5):1065-72

MedlineID: 68161656 PubMedID: 4867941

9. Boroff,D A., Dasgupta,B R., Fleck,U S.

Homogeneity and molecular weight of toxin of Clostridium botulinum type B.

(1968) *J Bacteriol* **95** (5):1738-44

MedlineID: 68239774 PubMedID: 4967772

10. DasGupta,B R., Boroff,D A., Cheong,K.

Isolation of chromatographically pure toxin of Clostridium botulinum type B.

(1968) *Biochem Biophys Res Commun* **32** (6):1057-63

MedlineID: 69077918 PubMedID: 4882877

11. Dasgupta,B R., Boroff,D A., Cheong,K.

Cation-exchange chromatography of Clostridium botulinum type A toxin on amberlite IRC-50 resin at pH 5.55.

(1968) *Biochim Biophys Acta* **168** (3):522-31

MedlineID: 69079036 PubMedID: 4973552

12. DasGupta,B R.

Interference by hydrogen peroxide in the assay for tryptophan with p-dimethylaminobenzaldehyde by the method of Spies and Chambers.

(1969) *Anal Biochem* **30** (2):284-7

MedlineID: 69286332 PubMedID: 5809670

13. Dasgupta,B R., Berry,L J., Boroff,D A.

Purification of Clostridium botulinum type A toxin.

(1970) *Biochim Biophys Acta* **214** (2):343-9

MedlineID: 71125115 PubMedID: 4993506

14. DasGupta,B R.
Activation of Clostridium botulinum type B toxin by an endogenous enzyme.
(1971) *J Bacteriol* **108** (3):1051-7
MedlineID: 72098777 PubMedID: 4945183
15. Dasgupta,B R., Sugiyama,H.
Isolation and characterization of a protease from Clostridium botulinum type B.
(1972) *Biochim Biophys Acta* **268** (3):719-29
MedlineID: 72214041 PubMedID: 4556539
16. DasGupta,B R., Sugiyama,H.
A common subunit structure in Clostridium botulinum type A, B and E toxins.
(1972) *Biochem Biophys Res Commun* **48** (1):108-12
MedlineID: 72229984 PubMedID: 5041870
17. Sugiyama,H., Oishi,I., Dasgupta,B R.
Evaluation of type A botulinal toxin assays that use antitoxin to crystalline toxin.
(1974) *Appl Microbiol* **27** (2):333-6
MedlineID: 74146361 PubMedID: 4856714
18. Sugiyama,H., DasGupta,B R., Oishi,I.
Disulfide-immunogenicity relationship of botulinal toxins.
(1974) *Proc Soc Exp Biol Med* **145** (4):1306-9
MedlineID: 74161950 PubMedID: 4133301
19. Sugiyama,H., DasGupta,B R., Yang,K H.
Toxicity of purified botulinal toxin fed to mice.
(1974) *Proc Soc Exp Biol Med* **147** (2):589-91
MedlineID: 75065850 PubMedID: 4438373
20. Sugiyama,H., Brenner,S L., Dasgupta,B R.
Detection of Clostridium botulinum toxin by local paralysis elicited with intramuscular challenge.
(1975) *Appl Microbiol* **30** (3):420-3

MedlineID: 76038594 PubMedID: 1180550

21. Dasgupta,B R., Sugiyama,H.
Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures.
(1976) *Infect Immun* **14** (3):680-6
MedlineID: 77005264 PubMedID: 965092
22. DasGupta,B R., Sugiyama,H.
Comparative sizes of type A and B botulinum neurotoxins.
(1977) *Toxicon* **15** (4):357-63
MedlineID: 77236736 PubMedID: 882998
23. DasGupta,B R., Sugiyama,H.
Inhibition of Clostridium botulinum types A and B hemagglutinins by sugars.
(1977) *Can J Microbiol* **23** (9):1257-60
MedlineID: 78001431 PubMedID: 332296
24. DasGupta,B R., Sugiyama,H.
Single chain and dichain forms of neurotoxin in type F Clostridium botulinum culture.
(1977) *Toxicon* **15** (5):466-71
MedlineID: 78014458 PubMedID: 906033
25. DasGupta,B R., Sugiyama,H.
Role of arginine residues in the structure and biological activity of botulinum neurotoxin types A and E.
(1980) *Biochem Biophys Res Commun* **93** (2):369-75
MedlineID: 80220288 PubMedID: 6770849
26. DasGupta,B R.
Electrophoretic analysis of Clostridium botulinum types A and B hemagglutinins.
(1980) *Can J Microbiol* **26** (8):992-7
MedlineID: 81111613 PubMedID: 7006771
27. DasGupta,B R., Rasmussen,S.
Role of amino groups in the structure and biological activity of botulinum neurotoxin types A and E.

(1981) *Biochem Biophys Res Commun* **101** (4):1209-15

MedlineID: 82068390 PubMedID: 6796082

28. Saccone,G T., DasGupta,B R., Pariza,M W.

Enhancement of N-hydroxy-2-aminofluorene bacterial mutagenicity by the soluble protein fraction from rat liver and partial purification of the enhancement activity.

(1981) *Cancer Res* **41** (11 Pt 1):4600-5

MedlineID: 82070083 PubMedID: 7030478

29. Dasgupta,B R., Pariza,M W.

Purification of two Clostridium perfringens enterotoxin-like proteins and their effects on membrane permeability in primary cultures of adult rat hepatocytes.

(1982) *Infect Immun* **38** (2):592-7

MedlineID: 83055805 PubMedID: 6292107

30. Simpson,L L., Dasgupta,B R.

Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships.

(1983) *J Pharmacol Exp Ther* **224** (1):135-40

MedlineID: 83085378 PubMedID: 6294275

STIC-ILL

Q.D.I. B.S.
Mic

From: Portner, Ginny
Sent: Wednesday, October 30, 2002 8:29 AM
T : STIC-ILL
Subject: neurotoxin

Biochim Biophys Acta 1993 Dec 14;1216(3):487-91

Related

Articles, Links

Nucleotide sequence of the gene coding for Clostridium botulinum (Clostridium argentinense) type G neurotoxin: genealogical comparison with other clostridial neurotoxins.

Campbell K, Collins MD, East AK.

Department of Microbiology, Institute of Food Research, Reading Laboratory, Earley G

Ginny Portner
CM1, Art Unit 1645
Room 7e13
Mail box 7e12
(703) 308-7543

STIC-ILL

Check cite

QRI.F4
Mic

Fr m: Portner, Ginny
Sent: Wednesday, October 30, 2002 8:43 AM
To: STIC-ILL
Subject: neurotoxin

1992, v. 91

FEMS Microbiol Lett 1992 Feb 1; ~~70~~ 69-72

Related

Articles, Links

Cloning of a Clostridium botulinum type B toxin gene fragment encoding the N-terminus of the heavy chain.

Jung HH, Rhee SD, Yang KH.

Department of Life Science, Korea Advanced Institute of Science and Technology, Taejon, Korea.

Ginny Portner
CM1, Art Unit 1645
Room 7e13
Mail box 7e12
(703) 308-7543

~~1990, v. 70~~

STIC-ILL

QB1. F4
Adams

From: Portner, Ginny
Sent: Wednesday, October 30, 2002 9:15 AM
T : STIC-ILL
Subject: neurotoxin
Importance: High

FEMS Microbiol Lett 1993 Apr 1;108(2):175-82

Related


Articles, Links

Nucleotide sequence of the gene coding for Clostridium barati type F neurotoxin: comparison with other clostridial neurotoxins.

Thompson DE, Hutson RA, East AK, Allaway D, Collins MD, Richardson PT.

Department of Microbiology, AFRC Institute of Food Research, Reading Laboratory, UK.

Ginny Portner
CM1, Art Unit 1645
Room 7e13
Mail box 7e12
(703) 308-7543



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search for

Limits Preview/Index History Clipboard De

Display Save Text Add to Clipboard Get Subsequence

1: A48940. bontoxilysin (EC ...[gi:477374]

Links

LOCUS A48940 1291 aa linear BCT 18-JUN-1999
DEFINITION bontoxilysin (EC 3.4.24.69) B precursor - Clostridium botulinum.
ACCESSION A48940
VERSION A48940 GI:477374
DBSOURCE pir: locus A48940;

summary: #length 1291 #molecular-weight 150801 #checksum 9744

; genetic: #gene bont/b

; superfamily: tetanus toxin

; PIR dates: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change 18-Jun-1999

KEYWORDS hydrolase; metalloproteinase; neurotoxin; transmembrane protein; zinc.

SOURCE Clostridium botulinum

ORGANISM Clostridium botulinum

Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae; Clostridium.

REFERENCE 1 (residues 1 to 1291)

AUTHORS Schmidt,J.J., Sathyamoorthy,V. and DasGupta,B.R.

TITLE Partial amino acid sequences of botulinum neurotoxins types B and E

JOURNAL Arch. Biochem. Biophys. 238 (2), 544-548 (1985)

MEDLINE 85197963

PUBMED 3888113

REFERENCE 2 (residues 1 to 1291)

AUTHORS Dasgupta,B.R. and Datta,A.

TITLE Botulinum neurotoxin type B (strain 657): partial sequence and similarity with tetanus toxin

JOURNAL Biochimie 70 (6), 811-817 (1988)

MEDLINE 89000987

PUBMED 3139097

REFERENCE 3 (residues 1 to 1291)

AUTHORS Kurazono,H., Mochida,S., Binz,T., Eisel,U., Quanz,M.,

Grebenstein,O., Wernars,K., Poulain,B., Tauc,L. and Niemann,H.

TITLE Minimal essential domains specifying toxicity of the light chains of tetanus toxin and botulinum neurotoxin type A

JOURNAL J. Biol. Chem. 267 (21), 14721-14729 (1992)

MEDLINE 92340509

PUBMED 1634516

REFERENCE 4 (residues 1 to 1291)

AUTHORS Whelan,S.M., Elmore,M.J., Bodsworth,N.J., Brehm,J.K., Atkinson,T. and Minton,N.P.

TITLE Molecular cloning of the Clostridium botulinum structural gene

encoding the type B neurotoxin and determination of its entire nucleotide sequence

JOURNAL Appl. Environ. Microbiol. 58 (8), 2345-2354 (1992)
 MEDLINE 92384550
 PUBMED 1514783

REFERENCE 5 (residues 1 to 1291)
 AUTHORS Schiavo,G., Benfenati,F., Poulain,B., Rossetto,O., Polverino de Laureto,P., DasGupta,B.R. and Montecucco,C.
 TITLE Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
 JOURNAL Nature 359 (6398), 832-835 (1992)
 MEDLINE 93063293
 PUBMED 1331807

REMARK annotation
 REFERENCE 6 (residues 1 to 1291)
 AUTHORS Campbell,K.D., Collins,M.D. and East,A.K.
 TITLE Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F
 JOURNAL J. Clin. Microbiol. 31 (9), 2255-2262 (1993)
 MEDLINE 94013372
 PUBMED 8408542

REFERENCE 7 (residues 1 to 1291)
 AUTHORS Szabo,E.A., Pemberton,J.M. and Desmarchelier,P.M.
 TITLE Direct Submission
 JOURNAL Submitted (~APR-1992) to the EMBL Data Library

COMMENT Botulinum neurotoxins inhibit neurotransmitter release from cholinergic synapses. This toxin is activated by cleavage into two chains linked by a disulfide bond.


FEATURES Location/Qualifiers
 source 1..1291
 /organism="Clostridium botulinum"
 /db_xref="taxon:1491"
 Protein 1..1291
 /product="bontoxilysin B precursor"
 /EC_number="3.4.24.69"
 /note="botulinum neurotoxin type B (BoNT/B)"
 Region 2..441
 /region_name="product"
 /note="bontoxilysin B light chain"
 Site 230
 /site_type="binding"
 /note="zinc (His)"
 Site 231
 /site_type="active"
 /note="Glu"
 Site 234
 /site_type="binding"
 /note="zinc (His)"
 Region 442..1291
 /region_name="product"
 /note="bontoxilysin B heavy chain"

ORIGIN

```

1 mpvtinnfnfny ndpidnnnii mneppfargt gryykafkit driwiipery tfgykpedfn
61 kssgifnrdrv ceyydpdyln tndkkniflq tmiklfnrik skplgeklle miingipylg
121 drrvpleefn tniasvtvnk lisnpgever kkgifanlii fpggpvlnen etidigiqnh
181 fasregfggi mqmkfcpeyv svfnvqenk gasifnrrgy fsdpalilmh elihvlhgly
241 gikvddlpiv pnekffmqqs tdaiqaeeely tfggqdpsii tpstdksiyd kvlqnfrgfv
301 drlnkvlvci sdpnininiy knkfkdkykf vedsegkysi dvesfdklyk slmfqftetn
361 iaenykiktr asyfsdslpp vkiknllrne iytieegfni sddkmekeyr gqnkainkqa
421 yeeiskehla vykiqmcksv kapgicidvd nedlffiadk nsfsddlskn erieyntqsn
481 yiendfpine lildtdlisk ielpsentel ltdfnvdvpv yekqpaikki ftdentifqy
541 lysqtfpldi rdisltssfd dallfsnkvy sffsmdyikt ankvv eaglf agwvkqivnd
601 fvieanksnt mdkiadisli vpyiglalnv gnetakgnfe nafeiagasi llefipelli
661 pvvgaflles yidnknkiik tidnaltkrn ekwsdmygli vaqwlstvtnt qfytikeygmy
721 kalnyqaqal eeiikyryni ysekeksnin idfndinskl neginqaidn innfingcsv

```



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed for

Limits Preview/Index History Clipboard Det

Display Summary Sort Save Text Clip Add

Show: 20 Items 61-80 Page 4 of 10
of 183 Select page: 1 2 3 4 5 6 7 8

Entrez
PubMed

- ☐ **61:** Switalska A, Trembowler P, Meisel H. Related Articles, L
[Immunogenic properties of type E botulinum toxoid]
Med Dosw Mikrobiol. 1965;17(4):305-11. Polish. No abstract available.
PMID: 5326421 [PubMed - indexed for MEDLINE]

PubMed
Services

- ☐ **62:** Oguma K, Syuto B, Iida H, Kubo S. Related Articles, L
Antigenic similarity of toxins produced by Clostridium
botulinum type C and D strains.
Infect Immun. 1980 Dec;30(3):656-60.
PMID: 6785231 [PubMed - indexed for MEDLINE]

- ☐ **63:** Oguma K, Iida H, Shiozaki M. Related Articles, L
Phage conversion to hemagglutinin production in Clostridium
botulinum types C and D.
Infect Immun. 1976 Sep;14(3):597-602.
PMID: 786888 [PubMed - indexed for MEDLINE]

Related
Resources

- ☐ **64:** Ligieza J, Reiss J, Michalik M. Related Articles, L
Chemiluminescence immunosorbent assay (CLISA) and a
possibility of the specific detection of soluble antigens
Clostridium botulinum type A.
Arch Immunol Ther Exp (Warsz). 1994;42(2):129-33.
PMID: 7503646 [PubMed - indexed for MEDLINE]

- ☐ **65:** Reiner E, Bayer FL. Related Articles, L

Botulism: a pyrolysis-gas-liquid chromatographic study.
J Chromatogr Sci. 1978 Dec 10;16(12):623-9.
PMID: 370136 [PubMed - indexed for MEDLINE]

- **66:** Inoue K, Fujinaga Y, Yokota K, Oguma K. Related Articles, L
[Structure and function of Clostridium botulinum progenitor
toxins]
Tanpakushitsu Kakusan Koso. 1997 Oct;42(13):2049-60. Review. Japanese
abstract available.
PMID: 9330571 [PubMed - indexed for MEDLINE]

- **67:** Johnson EA, Lin WJ, Zhou YT, Bradshaw M. Related Articles, L
Characterization of neurotoxin mutants in Clostridium
botulinum type A.
Clin Infect Dis. 1997 Sep;25 Suppl 2:S168-70. No abstract available.
PMID: 9310666 [PubMed - indexed for MEDLINE]

- **68:** Hatheway CL, McCroskey LM, Lombard GL, Dowell VR Jr. Related Articles, L
Atypical toxin variant of Clostridium botulinum type B
associated with infant botulism.
J Clin Microbiol. 1981 Dec;14(6):607-11.
PMID: 7037830 [PubMed - indexed for MEDLINE]

- **69:** Syuto B, Murayama S, Oguma K, Kubo S. Related Articles, L
Existence of the large molecules of immunoglobulin G with
another component.
Nippon Juigaku Zasshi. 1988 Feb;50(1):31-7. No abstract available.
PMID: 3283398 [PubMed - indexed for MEDLINE]

- **70:** Watanabe T, Sagane Y, Kouguchi H, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, Ohyama T. Related Articles, L
Molecular composition of progenitor toxin produced by
Clostridium botulinum type C strain 6813.
J Protein Chem. 1999 Oct;18(7):753-60.
PMID: 10691185 [PubMed - indexed for MEDLINE]

- ☐ **71:** Poxton IR. Related Articles, L
Demonstration of the common antigens of Clostridium botulinum, C. sporogenes and C. novyi by an enzyme-linked immunosorbent assay and electroblot transfer.
J Gen Microbiol. 1984 Apr;130 (Pt 4):975-81.
PMID: 6376703 [PubMed - indexed for MEDLINE]
- ☐ **72:** Ohishi I. Related Articles, L
Activation of botulinum C2 toxin by trypsin.
Infect Immun. 1987 Jun;55(6):1461-5.
PMID: 3570475 [PubMed - indexed for MEDLINE]
- ☐ **73:** DasGupta BR, Sathyamoorthy V. Related Articles, L
Purification and amino acid composition of type A botuli neurotoxin.
Toxicon. 1984;22(3):415-24.
PMID: 6382680 [PubMed - indexed for MEDLINE]
- ☐ **74:** Wilde C, Aktories K. Related Articles, L
The Rho-ADP-ribosylating C3 exoenzyme from Clostridi botulinum and related C3-like transferases.
Toxicon. 2001 Nov;39(11):1647-60. Review. No abstract available.
PMID: 11595628 [PubMed - indexed for MEDLINE]
- ☐ **75:** Bulatova TI, Matveev KI. Related Articles, L
[The antigenic structure of the toxins of Clostridium botulinum, type C strains, isolated in the USSR]
Zh Mikrobiol Epidemiol Immunobiol. 1965 Aug;42(8):79-84. Russian. No abstract available.
PMID: 5334428 [PubMed - indexed for MEDLINE]
- ☐ **76:** Swaminathan S, Eswaramoorthy S. Related Articles, L
Crystallization and preliminary X-ray analysis of Clostridi botulinum neurotoxin type B.
Acta Crystallogr D Biol Crystallogr. 2000 Aug;56 (Pt 8):1024-6.
PMID: 10944343 [PubMed - indexed for MEDLINE]

☐ **77:** Gamboa MM, Rodriguez E, Fernandez B. Related Articles, L
[Clostridium botulinum in Costa Rica soils]
Rev Biol Trop. 1993 Dec;41(3A):359-63. Spanish.
PMID: 7701075 [PubMed - indexed for MEDLINE]

☐ **78:** Fujii N, Kimura K, Yokosawa N, Oguma K, Yashiki T, Takeshi K, Ohyama T, Isogai E, Isogai H. Related Articles, L
Similarity in nucleotide sequence of the gene encoding nontoxic component of botulinum toxin produced by toxigenic Clostridium butyricum strain BL6340 and Clostridium botulinum type E strain Mashike.
Microbiol Immunol. 1993;37(5):395-8.
PMID: 8355622 [PubMed - indexed for MEDLINE]

☐ **79:** Strom MS, Eklund MW, Poysky FT. Related Articles, L
Plasmids in Clostridium botulinum and related Clostridium species.
Appl Environ Microbiol. 1984 Nov;48(5):956-63.
PMID: 6391384 [PubMed - indexed for MEDLINE]

☐ **80:** Lin WJ, Johnson EA. Related Articles, L
Genome analysis of Clostridium botulinum type A by pulsed-field gel electrophoresis.
Appl Environ Microbiol. 1995 Dec;61(12):4441-7.
PMID: 8534108 [PubMed - indexed for MEDLINE]

Display	Summary	Sort	Save	Text	Clip Add
---------	---------	------	------	------	----------

Show: Items 61-80 Page 4 of 10
of 183 Select page: 1 2 3 4 5 6 7 8 9 10

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM

Search PubMed ☒ for Go Clear

Limits Preview/Index History Clipboard Det

Display Abstract ☒ Sort ☒ Save Text Clip Add

☐ 1: Curr Microbiol 1994
Feb;28(2):101-10

Related Articles,

Entrez
PubMed

Nucleotide sequence of the gene coding for non-proteolytic *Clostridium botulinum* type B neurotoxin: comparison with other clostridial neurotoxins.

Hutson RA, Collins MD, East AK, Thompson DE.

PubMed
Services

Department of Microbiology, AFRC Institute of Food Research, Reading Laboratory, UK.

Related
Resources

The neurotoxin gene of non-proteolytic *Clostridium botulinum* type B (strain Eklund 17B) was cloned as a series of overlapping polymerase chain reaction (PCR) fragments generated with primers designed to conserved regions of published botulinal toxin (BoNT) sequences. The 3' end of the gene was obtained by using primers designed to the determined sequence of non-proteolytic BoNT/B and a published downstream region of BoNT/B gene from a proteolytic strain. Translation of the nucleotide sequence derived from cloned PCR fragments demonstrated that the gene encodes a protein of 1291 amino acid residues. Comparative alignment of the derived BoNT/B sequence with those of other published botulinal neurotoxins revealed



CGCTCAGGATACGACTTCGGGCTAGAGATCGGATCCCGGCGGATTATTATATAGCTCGATCGATC1
 TTCTCTATATCGGCGGATGGGATATATACACACACACCGGCGGATAGCATGACTGATCTA
 CCCCCTA
 CACAGACTACGCTA

Nucleotide

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM B

Search for

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Data](#)

☐ 1: X71343. *C.botulinum* type ...[gi:296148]

[Links](#)

LOCUS CBBONTB 4051 bp DNA linear BCT 20-APR-1994

DEFINITION *C.botulinum* type B gene for neurotoxin.

ACCESSION X71343

VERSION X71343.1 GI:296148

KEYWORDS boNT/B gene; botulinum neurotoxin type B; neurotoxin type B.

SOURCE *Clostridium botulinum*

ORGANISM *Clostridium botulinum*
 Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
 Clostridium.

REFERENCE 1 (bases 1 to 4051)

AUTHORS Hutson,R.A., Collins,M.D., East,A.K. and Thompson,D.E.

TITLE Nucleotide sequence of the gene coding for non-proteolytic
Clostridium botulinum type B neurotoxin: comparison with other
 clostridial neurotoxins

JOURNAL Curr. Microbiol. 28 (2), 101-110 (1994)

MEDLINE 94122659

REFERENCE 2 (bases 1 to 4051)

AUTHORS Hutson,R.A.

TITLE Direct Submission

JOURNAL Submitted (06-APR-1993) R.A. Hutson, AFRC Institute of Food
 Research, Reading Laboratory, Microbiology Dept, Earley Gate,
 Whiteknights Road, Reading, RG6 2EF, UK

FEATURES Location/Qualifiers

source 1..4051
 /organism="Clostridium botulinum"
 /strain="Eklund 17B ATCC25765"
 /isolate="type B"
 /db_xref="taxon:1491"
 /clone="pCBOTB1-8"

RBS 83..91

gene 97..3972
 /gene="bont/b"

CDS 97..3972
 /gene="bont/b"
 /codon_start=1
 /transl_table=11
 /product="BoNT/B"
 /protein_id="CAA50482.1"
 /db_xref="GI:296149"
 /db_xref="SPTREMBL:Q08077"

/translation="MPVTINNFNNDPIDNDNIIMMEPPFARGTGRIYKAFKITDRIW
 IIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFFQTLIKLFNRIKSK
 PLGEKLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLII
 FGPGPVLNENETIDIGIQNHFAFREGFGGIMQMKFCPEYVSFNNVQENKGASIFNRR
 GYFSDPALILMHELIHVLHGLYGIKVDLPIVPNEKKFFMQSTDITQAEELYTFGGQD
 PSIIISPSTDKSIYDKVLQNFGRGIVDRNLKVLVCISDPNININIKYKFKDKYKFVEDS
 EGKYSIDVESFNKLYKSLMLGFTEINIAENYKIKTRASYFSDSLPPVKIKNLLDNEIY

TIEEGFNISDKNMGKEYRGONKAINQAYEEISKEHLAVYKIQMCKSVKVPKICIDVD
 NENLFFIADKNSFSDLSKNERVEYNTQNNYIGNDFPINELILDLDLISKIELPSENT
 ESLTDFNVDVPVYEKQPAIKKVFTDENTIFQYLYSQTFPLNIRDISLTSFDDALLVS
 SKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVDDFVIEANKSS'TMDKIADISLIVPYI
 GLALNVGDETAKNFESAFEIAGSSILLEFIPELLIPVVGVFLLSEYIDNKNKI I KTI
 DNALTKRVEKWIDMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYKYN
 YSEEEKSNININFNDINSKLNLDGINQAMDNDINDFINECSVSYLMKKMIPLAVKKLLDF
 DNTLKKNLLNYIDENKLYLIGSVEDEKSKVDKYLKTIIPFDLSTYSNIEILIKIFNKY
 NSEILNNIILNLRYRDNNLIDLSGYAKVEVDGVKLNNDKNQFKLTSSADSKIRVTQN
 QNIIFNSMFLDFSVSFWIRIPKYRNDIDIQNYIHNEYTIINCMKNNSGWKISIRGNRII
 WTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLDNAKIYINGTLESNMDIKD
 IGEVIVNGEITFKLDGPDVDRTOFIWMKYFSIFNTQLNQSNIKEIYKIQSYSEYKDFW
 GNPLMYNKEYYMFNAGNKNYSIKLVKDSVGEILIRSKYNQNSNYINRNLVIGEKF
 IRRESNSQSINDDIVRKEDYIHLDLVLHHEEWRVYAYKYFKEQEKLFLSIISDSNEF
 YKTIEIKEYDEQPSYSCQLLFFKDEESTDDIGLIGIHRFYESGVLKRYKDYFCISKW
 YLKEVKRKPYSNLCNWFIPKDEGWTE"

BASE COUNT 1679 a 384 c 645 g 1343 t
 ORIGIN

1	gataataata	atataataat	gatgacaata	tacctaaagc	tgcacattta	tggacattaa
61	aagggatata	aacttaaaat	aaggaggaga	atatttatgc	cagttacaat	aaataatttt
121	aattataatg	atcctattga	taatgacaat	attattatga	tggaaacctcc	atttgcaagg
181	ggtacgggga	gatattataa	agctttttaa	atcacagatc	gtatttggat	aatacccgaa
241	agataatactt	ttggatataa	acctgaggat	tttaataaaa	gttcaggat	ttttaataga
301	gatgtttgtg	aatattatga	tccagattac	ttaaatacca	atgataaaaa	gaataatatt
361	ttccaaacat	tgatcaagtt	atttaataga	atcaaatcaa	aaccattggg	tgaataagtt
421	ttagagatga	ttataaatgg	tataccttat	cttgagagata	gacgtgttcc	actcgaagag
481	tttaacacaa	acattgctag	tgtaactgtt	aataaattaa	ttagtaatcc	aggagaagtg
541	gagcgaaaaa	aaggtatttt	cgcaaattta	ataatatttg	gacctgggcc	agttttaaat
601	gaaaatgaga	ctatagatat	aggtatacaa	aatcattttg	catcaaggga	aggctttggg
661	ggtataatgc	aaatgaaatt	ttgtccagaa	tatgtaagcg	tatttaataa	tgttcaagaa
721	aacaaaggcg	caagtatat	taatagacgt	ggatattttt	cagatccagc	cttgatatta
781	atgcatgaac	ttatacatgt	tttgcatgga	ttatatggca	ttaaagtaga	tgatttacca
841	attgtaccaa	atgaaaaaaa	attttttatg	caatctacag	atactatata	ggcagaagaa
901	ctatatacat	ttggaggaca	agatcccagc	atcatatctc	cttctacaga	taaaagtatc
961	tatgataaag	ttttgcaaaa	ttttaggggg	atagttgata	gacttaacaa	ggtttttagt
1021	tgcatatcag	atcctaacat	taacattaat	atatataaaa	ataaatttaa	agataaatat
1081	aaattcgttg	aagattctga	aggaaaatat	agtatagatg	tagaaagttt	caataaatta
1141	tataaaaagct	taatgttagg	ttttacagaa	attaatatag	cagaaaatta	taaaataaaa
1201	actagagctt	cttatttttag	tgattcctta	ccaccagtaa	aaataaaaaa	tttatttagat
1261	aatgaaatct	atactataga	ggaaggggtt	aatatatctg	ataaaaaatat	gggaaaagaa
1321	tataggggtc	agaataaaagc	tataaataaa	caagccttatg	aagaaatcag	caaggagcat
1381	ttggctgtat	ataagatata	aatgtgtaaa	agtgttaaag	ttccagggaat	atgtattgat
1441	gtcgataatg	aaaattttgtt	ctttatagct	gataaaaaata	gtttttcaga	tgatttatct
1501	aaaaatgaaa	gagtagaata	taatacacag	aataattata	taggaaatga	ctttcctata
1561	aatgaattaa	ttttagatac	tgatttaata	agtaaaatag	aattaccaag	tgaaaatata
1621	gaatcactta	ctgatttttaa	tgtatagttt	ccagtatatg	aaaaacaacc	cgctataaaa
1681	aaagttttta	cagatgaaaa	taccatcttt	caatattttat	actctcagac	atttcctcta
1741	aatataagag	atataagttt	aacatcttta	tttgatgatg	cattattagt	ttctagcaaa
1801	gtttattcat	ttttttctat	ggattatatt	aaaactgcta	ataaagtagt	agaagcagga
1861	ttatttgcag	gttgggtgaa	acagatagta	gatgattttg	taatcgaagc	taataaaaagc
1921	agtactatgg	ataaaaattgc	agatataatc	ctaattgttc	cttatatagg	attagcttta
1981	aatgtaggag	atgaaacagc	taaaggaaat	tttgaaagtg	cttttgagat	tgaggagatcc
2041	agtattttac	tagaattttat	accagaactt	ttataacctg	tagttggagt	ctttttatta
2101	gaatcatata	ttgacaataa	aaataaaaatt	attaaaacaa	tagataatgc	tttaactaaa
2161	agagtggaaa	aatggattga	tatgtacgga	ttaatagtag	cgcaatggct	ctcaacagtt
2221	aatactcaat	tttatacaat	aaaagaggga	atgtataagg	ctttaaatta	tcaagcacia
2281	gcattggaag	aaataataaa	atacaaatat	aatatatatt	ctgaagagga	aaagtcaaat
2341	attaacatca	atttttaata	tataaattct	aaacttaaty	atggatttaa	ccaagctatg
2401	gataatataa	atgatttttat	aaatgaatgt	tctgtatcat	attttaatgaa	aaaaatgatt
2461	ccattagctg	taaaaaaaatt	actagacttt	gataataactc	tcaaaaaaaa	tttattaaat
2521	tatatagatg	aaaataaaatt	atattttaatt	ggaagtgtag	aagatgaaaa	atcaaaaagta
2581	gataaaatact	tgaaaaccat	tataccattt	gatctttcaa	cgtatttctaa	tattgaaata
2641	ctaataaaaa	tatttaataa	atataatagc	gaaatttttaa	ataaatattat	cttaaattta
2701	agatatagag	ataataattt	aatagatttta	tcaggatatg	gagcaaaagg	agaggatatat
2761	gatgggggtca	agcttaatat	taaaaatcaa	tttaaatata	ctagttcagc	agatagtaag

WEST Search History

DATE: Wednesday, October 30, 2002

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=AND

L1	fragment near3 c	6601	L1
	L1 same (neurotox\$ or toxin or toxins or endopeptidase or endoproteinase or		
L2	endoprotease or metalloproteinase or metalloprotease or metallopeptidase or clostrid\$ or botulin\$ or botulis\$)	277	L2
L3	L2 same (\$type near b)	0	L3
L4	L2 same (\$type near5 b)	8	L4

END OF SEARCH HISTORY

WEST Search History

DATE: Wednesday, October 30, 2002

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set</u> <u>Name</u>
side by side			result set
	<i>DB=USPT; PLUR=YES; OP=AND</i>		
L1	heavy.clm. same chain.clm.	931	L1
L2	L1 and clostrid\$	16	L2
L3	L1 and botuli\$	12	L3
L4	(L3 or l2) and (coding or nucleic or nucleotide or dna or cdna or mrna or rna or genetic or chromosome or chromosomal or sequence or recombinant)	18	L4
L5	(4683195 4683202 4965188)! [pn]	3	L5
L6	(clostrid\$ or botuli\$ or neurotox\$ or bontoxylylsin\$ or \$endopeptidases or \$metalloproteinases or binary).ti,ab,clm.	33495	L6
L7	L6 and (heavy near5 chain)	89	L7
L8	L6 and (domain or carbox\$)	3091	L8
L9	L6 and (domain or domains or carboxy\$ or cterminal or c-terminal)	3125	L9
L10	L9 and (botx or botox or bnx or bottox or bot or serotype or sero-type of botulinum or botulism or btx or bont\$)	105	L10

END OF SEARCH HISTORY

A48940. bontoxilysin (EC ...[gi:477374]

Links

LOCUS A48940 1291 aa linear BCT 18-JUN-1999
DEFINITION bontoxilysin (EC 3.4.24.69) B precursor - Clostridium botulinum.
ACCESSION A48940
VERSION A48940 GI:477374
DBSOURCE pir: locus A48940;

summary: #length 1291 #molecular-weight 150801 #checksum 9744
;
genetic: #gene bont/b
;
superfamily: tetanus toxin
;
PIR dates: 19-Dec-1993 #sequence_revision 18-Nov-1994 #text_change
18-Jun-1999

KEYWORDS hydrolase; metalloproteinase; neurotoxin; transmembrane protein;
zinc.

SOURCE Clostridium botulinum
ORGANISM Clostridium botulinum
Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
Clostridium.

REFERENCE 1 (residues 1 to 1291)
AUTHORS Schmidt,J.J., Sathyamoorthy,V. and DasGupta,B.R.
TITLE Partial amino acid sequences of botulinum neurotoxins types B and E
JOURNAL Arch. Biochem. Biophys. 238 (2), 544-548 (1985)
MEDLINE 85197963
PUBMED 3888113

REFERENCE 2 (residues 1 to 1291)
AUTHORS Dasgupta,B.R. and Datta,A.
TITLE Botulinum neurotoxin type B (strain 657): partial sequence and
similarity with tetanus toxin
JOURNAL Biochimie 70 (6), 811-817 (1988)
MEDLINE 89000987
PUBMED 3139097

REFERENCE 3 (residues 1 to 1291)
AUTHORS Kurazono,H., Mochida,S., Binz,T., Eisel,U., Quanz,M.,
Greibenstein,O., Wernars,K., Poulain,B., Tauc,L. and Niemann,H.
TITLE Minimal essential domains specifying toxicity of the light chains
of tetanus toxin and botulinum neurotoxin type A
JOURNAL J. Biol. Chem. 267 (21), 14721-14729 (1992)

PUBMED 1634516

AUTHORS Whelan,S.M., Elmore,M.J., Bodsworth,N.J., Brehm,J.K., Atkinson,T.
and Minton,N.P.

JOURNAL Appl. Environ. Microbiol. 58 (8), 2345-2354 (1992)

PUBMED 1514783

AUTHORS Schiavo,G., Benfenati,F., Poulain,B., Rossetto,O., Polverino de Laureto,P., DasGupta,B.R. and Montecucco,C.

JOURNAL Nature 359 (6398), 832-835 (1992)

PUBMED 1331807

REFERENCE 6 (residues 1 to 1291)

TITLE Gene probes for identification of the botulinal neurotoxin gene and specific identification of neurotoxin types B, E, and F

MEDLINE 94013372

PUBMED 8408542

AUTHORS Szabo, E.A., Pemberton, J.M. and Desmarchelier, P.M.

JOURNAL Submitted (~APR-1992) to the EMBL Data Library

COMMENT Botulinum neurotoxins inhibit neurotransmitter release from cholinergic synapses. This toxin is activated by cleavage into two chains linked by a disulfide bond.

FEATURES	Location/Qualifiers
----------	---------------------

```
source      1..1291
            /organism="Clostridium botulinum"
            /db_xref="taxon:1491"
```

Protein 1..1291
/product="bontoxilysin B precursor"
/EC_number="3.4.24.69"
/note="botulinum neurotoxin type B (BoNT/B)"

```
Region      2..441
            /region_name="product"
            /note="bontoxilysin B light chain"
```

Site 230
/site_type="binding"
/note="zinc (His)"
Site 231
/site_type="active"
/note="Glu"
Site 234
/site_type="binding"
/note="zinc (His)"
Region 442..1291
/region_name="product"
/note="bontoxilysin B heavy chain"

ORIGIN

1 mpvtinnfnyn ndpidnnnii mmeppfargt gryykafkit driwiipery tfgykpedfn
61 kssgifnrdr ceyydpdyln tndkkniflq tmiklfnrik skplgeklle miingipylg
121 drrvpleefn tniasvtvkn lisnpgever kkgifanlii fgpgpvlnen etidigiqnh
181 fasregfggi mqmkfcpeyv svfnnvqenk gasifnrrgy fsdpalilmh elihvlhgly
241 gikvddlpiv pnekkffmqst daiqaely tfggqdpssii tpstdksiyd kvlnqfrgiv
301 drlnkvlvci sdpnininiy knkfkdkykf vedsegkysi dvesfdklyk slmfqftetn
361 iaenykiktr asyfsdslpp vkiknlldne iytieegfni sddmekeyr gqnkainkqa
421 yeeiskehla vykiqmcksv kapgicidvd nedlffiadk nsfsddlskn erieyntqsn
481 yiendfpine lildtdlisk ielpsentess ltdfnvdvpv yekqpaikki ftdentifqy
541 lysqtfpldi rdisltssfd dallfsnkvy sffsmdyikt ankvveaglf agwvkqivnd
601 fvieanksnt mdkiadisli vpyiglalnv gnetakgnfe nafeiagasi llefipelli
661 pvvgafiles yidnknkiik tidnaltkrn ekwsdmygli vaqwlstvtnt qfytiqegmy
721 kalnyqaqal eeiikyryni ysekeksnin idfndinskl neginqaidn innfingcsv
781 sylmkkmipl aveklldfdn tlkknllnyi denklyligs aeyekskvkn yltkimpfdl
841 siyndtili emfnkynsei lnniilnlry kdnnlidlsg ygakvevydg velndknqfk
901 ltssanskir vtqnqniifn svfldfsvsf wiripkyknd giqnyihney tiincmkns
961 gwkisirgnr iwtliding ktksvffeyn irediseyin rwffvtitnn lnnakiying
1021 klesntdikd ireviangei ifklgdidir tqfiwmkyfs ifntelsqsn ieerykiqsy
1081 seylkdfwgn plmynkeyym fnagnknsyi klkddspvge iltrskynqn skyinyrdly
1141 igeckfiirrk snsqsinddi vrkedyiyld ffnlnqewrv ytykyfkkee eklflapisd
1201 sdefyntiqi keydeqptys cqlfkdkdee stdeigligi hrifiesgivf eeykdyfcis
1261 kwylkevkrk pynlklgcnw qfipkdegwt e

//

Revised: July 5, 2002.


WEST Search History

DATE: Wednesday, October 30, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> result set
side by side			
<i>DB=USPT; PLUR=YES; OP=AND</i>			
L1	receptor near5 binding near5 domain	2345	L1
L2	receptor near5 binding near5 (moiety or portion)	1345	L2
L3	L2 or l1	3232	L3
L4	L3 same (clostrid\$ or botul\$ or neurotox\$)	18	L4
L5	(h-c or h-chain or hchain or (h near2 c)) and (clostrid\$ or botul\$ or neurotox\$)	2166	L5
L6	(h-c or h-chain or hchain or (h near2 c)) same (clostrid\$ or botul\$ or neurotox\$)	86	L6
L7	target\$ near5 (moiety or domain or binder or portion)	18279	L7
L8	L7 same (type near b)	14	L8
L9	L8 and clostrid\$	0	L9
L10	L8 and neurotoxin	0	L10
L11	L8 and botulinum	0	L11
L12	L7 same clostrid\$	10	L12
L13	hc near5 (fragment or moiety or portion or domain)	520	L13
L14	L13 same (botulinum or botulism or neurotoxin or neuro-toxin or clostrid\$)	3	L14
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>			
L15	hc near5 (fragment or moiety or portion or domain)	718	L15

L16 L15 not l13 198 L16
L17 L16 same (clostrid\$ or botul\$ or neurotox\$) 5 L17

END OF SEARCH HISTORY



Search Nucleotide for

Limits Preview/Index History Clipboard De

Display default Save Text Add to Clipboard Get Subsequence

Links

1 of 3

SYIANKVLTVQTIDNALS KRNEKWDEVYKYIVTNWLAKVNTQIDLRKKMKEALENQA
 EATKALINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMN
 SMIPYGVKRLEDFDASIKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDI PFQLSKY
 VDNQRLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQI
 QLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNS
 GWKVS LNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIY
 INGR LIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLY
 DNQSN SGILKDFWGDYLDKPYMYMLNLYDPNKYVDVNNVVGIRGYMYLKGPRGSVMTT
 NIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEK
 ILSALEIPDVGNLSQVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGHFQFNNAKLKLV
 ASNWYNRQIERSSRTLGCSEWEIFPVDDGWGERPL"

misc feature

4400..4432

/note="potential terminator; putative"

BASE COUNT 1934 a 517 c 756 g 1628 t
 ORIGIN

```

1 aagcttcttaa atttaaatta ttaagtataa atccaaataa acaatatgtt caaaaacttg
61 atgaggtaaat aattttctgta ttagataata tggaaaaata tatagatata tctgaagata
121 atagattgca actaatagat aacaaaaata acgcaaagaa gatgataatt agtaatgata
181 tattttatttc caattgttta accctatctt ataacggtaa atatatatgt ttatctatga
241 aagatgaaaa ccataattgg atgatatgta ataatgatat gtcaaagtat ttgtatttat
301 ggatcatttaa ataattaata atttaattaa ttttaaatat tataagagggt gttaaatatg
361 ccatttggtta ataaacaatt taattataaa gatcctgtaa atgggtgttg tattgcttat
421 ataaaaattc caaatgcagg acaaatgcaa ccagtaaaag cttttaaaat tcataataaa
481 atatgggtta ttcagaaag agatacattt acaaatcctg aagaaggaga tttaaatcca
541 ccaccagaag caaaacaagt tccagtttca tattatgatt caacatattt aagtacagat
601 aatgaaaaag ataattattt aaaggagggt acaaaattat ttgagagaat ttattcaact
661 gatccttgga gaattgtgtt aacatcaata gtaaggggaa taccattttg ggggtggaagt
721 acaatagata cagaattaaa agttattgat actaattgta ttaatgtgat acaaccagat
781 ggtagttata gatcagaaga acttaattct gtaataatag gaccctcagc tgatattata
841 cagtttgaat gtaaaagctt tggacatgaa gttttgaatc ttacgcgaaa tggttatggc
901 tctactcaat acattagatt tagcccagat tttacatttg gttttgagga gtcacttgaa
961 gttgatacaa atcctctttt aggtgcaggc aaatttgcta cagatccagc agtaacatta
1021 gacatgaac ttatacatgc tggacataga ttatatggaa tagcaattaa tccaatagg
1081 gttttttaaag taaatactaa tgcctattat gaaatgagtg gggttagaagt aagctttgag
1141 gaacttagaa catttggggg acatgatgca aagtttatag atagtttaca ggaaaacgaa
1201 tttcgtctat attattataa taagttttaa gatatagcaa gtacacttaa taaagctaaa
1261 tcaatagtag gtactactgc ttcattacag tatatgaaaa atgtttttta agagaaatat
1321 ctctatctg aagatacatc tggaaaattt tcggtagata aattaaaatt tgataagtta
1381 tacaaaatgt taacagagat ttacacagag gataattttg ttaagttttt taaagctact
1441 aacagaaaaa catatttgaa tttgataaaa gccgtattta agataaatat tccaactaag
1501 gtaaaattaca caatatatga tggatttaat ttaagaaata caaatttagc agcaaacctt
1561 aatgggtcaaa atacagaaat taataatatg aattttacta aactaaaaaa ttttactgga
1621 ttgtttgaat ttataagtt gctatgtgta agagggataa taacttctaa aactaaatca
1681 ttagataaaag gatacaataa ggcattaaat gatttatgta tcaaagttaa taattgggac
1741 ttgtttttta gtccttcaga agataatttt actaatgatc taaataaagg agaagaaatt
1801 acatctgata ctaatataga agcagcagaa gaaaatatta gtttagattt aatacaacaa
1861 tattatttaa cctttaattt tgataattgaa cctgaaaata tttcaataga aaatctttca
1921 agtgacatta taggccaatt agaacttatg cctaatatag aaagattttc taattgaaaa
1981 aagtatgagt tagataaata tactatgttc cattatcttc gtgctcaaga atttgaacat
2041 ggtaaatcta ggattgcttt aacaaattct gttaacgaag cattattaaa tcctagtcgt
2101 gtttatacat ttttttcttc agactatgta aagaaagtta ataaagctac ggaggcagct
2161 atgttttttag gctgggtaga acaattagta tatgatttta ccgatgaaac tagcgaagta
2221 agtactacgg ataaaattgc ggatataact ataattattc catatatagg acctgcttta
2281 aatataggta atatgttata taaagatgat tttgtagggt ctttaatat ttcaggagct
2341 gttattctgt tagaatttat accagagatt gcaataacct tatttaggtac ttttgcaact
2401 gatatcataa ttgcgaataa ggttctaacc gttcaaacia tagataatgc ttttagtaaa
2461 agaaatgaaa aatgggatga ggtctataaa tatatagtaa caaattggtt agcaaagggt
2521 aatacacaga ttgatcta atagaaaaaa atgaaagaag ctttagaaaa tcaagcagaa
2581 gcaacaaagg ctataataaa ctatcagtat aatcaatata ctgaggaaga gaaaaataat
2641 attaatttta atattgatga tttaagttcg aaacttaatg agtctataaa taaagctatg
2701 attaatataa ataaattttt gaatcaatgc tctgtttcat atttaatgaa ttctatgatc
2761 ccttatggtg ttaaacggtt agaagatttt gatgctagtc ttaaagatgc attattaaag
2821 tatatatatg ataatagagg aactttaatt ggtcaagtag atagattaaa agataaagtt
2881 aataatacac ttagtacaga tatacctttt cagctttcca aatacgtaga taatcaaaga
2941 ttattatcta catttactga atataatta aatattatta atacttctat attgaattta

```

```

3001 agatatgaaa gtaatcattt aatagactta tctaggtatg catcaaaaat aaatattggt
3061 agtaaagtaa attttgatcc aatagataaa aatcaaattc aattatttaa tttagaaagt
3121 agtaaaattg aggtaatttt aaaaaatgct attgtatata atagtatgta tgaaaatttt
3181 agtactagct tttggataag aattcctaag tattttaaca gtataagtct aaataatgaa
3241 tatacaataa taaattgtat ggaaaataat tcaggatgga aagtatcact taattatggt
3301 gaaataatct ggactttaca ggatactcag gaaataaaac aaagagtagt ttttaaatac
3361 agtcaaatga ttaatatatc agattatata aacagatgga tttttgtaac tatcactaat
3421 aatagattaa ataactctaa aatttatata aatggaagat taatagatca aaaaccaatt
3481 tcaaatttag gtaatatcca tgctagtaat aatataatgt ttaaattaga tggttgtaga
3541 gatacacata gatataattg gataaaatat tttaatcttt ttgataagga attaaatgaa
3601 aaagaaatca aagatttata tgataatcaa tcaaattcag gtatttttaa agacttttgg
3661 ggtgattatt tacaatatga taaaccatac tatatgttaa atttatatga tccaaataaa
3721 tatgtcgatg taaataatgt aggtattaga gggtatatgt atcttaaagg gcctagaggt
3781 agcgtaatga ctacaaacat ttattttaa tcaagtttgt atagggggac aaaattttatt
3841 ataaaaaaat atgcttctgg aaataaagat aatattgtta gaaataatga tcgtgtatat
3901 attaatgtag tagttaaaaa taaagaatat aggttagcta ctaatgcac acaggcaggc
3961 gtagaaaaaa tactaagtgc attagaaata cctgatgtag gaaatctaag tcaagtagta
4021 gtaatgaagt caaaaaatga tcaaggaata acaataaaat gcaaaatgaa tttacaagat
4081 aataatggga atgatatagg ctttatagga tttcatcagt ttaataatat agctaaacta
4141 gtagcaagta attggtataa tagacaaata gaaagatcta gtaggacttt ggggttgctca
4201 tgggaattta ttctgtaga tgatggatgg ggagaaaggc cactgtaatt aatctcaaac
4261 tacatgagtc tgtcaagaat tttctgtaaa catccataaa aattttaaaa ttaatatggt
4321 taagaataac tagatatgag tattgtttga actgcccctg tcaagtagac aggtaaaaaa
4381 ataaaaatta agatactatg gtctgatttc gatattctat cggagtcaga ctttttaact
4441 tttcttgtat cctttttgta ttgtaaaact ctatgtattc atcaattgca agttccaatt
4501 agtcaaaatt atgaaacttt ctaagataat acatttctga ttttataatt tcccaaaatc
4561 cttccatagg accattatca atacatctac caactcgaga catactttga gttgcgccta
4621 tctcattaag tttattcttg aaagatttac ttgtatattg aaaaccgcta tcaactgtgaa
4681 aaagtggact agcatcagga ttggaggtaa ctgctttatc aaagggttca aagacaagga
4741 cgttgttatt tgattttcca agtacatagg aaataatgct attatcatgc aaatcaagta
4801 tttcactcaa gtacgccttt gtttcgtctg ttaac

```

//

Revised: July 5, 2002.

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Oct 21 2002 11:56:56

WEST

Generate Collection

Print

L12: Entry 2 of 10

File: USPT

Oct 8, 2002

DOCUMENT-IDENTIFIER: US 6461617 B1

TITLE: Recombinant toxin fragments

Abstract Text (1):

A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

Brief Summary Text (9):

(B) Clostridial Neurotoxin Heavy Chain H.sub.N Domain: a portion of the heavy chain which enables translocation of that portion of the neurotoxin molecule such that a functional expression of light chain activity occurs within a target cell. the domain responsible for translocation of the endopeptidase activity, following binding of neurotoxin to its specific cell surface receptor via the binding domain, into the target cell. the domain responsible for formation of ion-permeable pores in lipid membranes under conditions of low pH. the domain responsible for increasing the solubility of the entire polypeptide compared to the solubility of light chain alone.

WEST



Generate Collection

Print

L14: Entry 2 of 3

File: USPT

Sep 3, 2002

DOCUMENT-IDENTIFIER: US 6444209 B1

TITLE: Hybrid botulinal neurotoxins

Brief Summary Text (12):

The biologically active neurotoxin of C. botulinum is a dichain molecule of ca. 150 kD in molecular weight. The molecule is composed of two 10 fragments or chains that are termed the heavy chain (Hc, ca. 100 kD) and the light chain (Lc, ca. 50 kD) that are covalently connected by one disulfide bond (FIG. 1). The neurotoxin is synthesized by the organism as a single polypeptide called the protoxin and undergoes post-translational processing termed nicking to generate the two separate chains by at least one protease (Yokosawa, N., et al., J. Gen. Microbiol. 132:1981-1988, 1986; Krysinski, E. and Sugiyama, H., Appl. Environ. Microbiol. 41:675-678, 1981). The two chains are covalently bound through a disulfide bridge. The nicking event occurs in the culture fluid for proteolytic C. botulinum and through the activity of an exogenous enzyme such as trypsin in non-proteolytic strains (Yokosawa, N., et al., supra, 1986; DasGupta, B., J. Physiol. (Paris) 84:220-228, 1990; Kozaki, S., et al., FEMS Microbiol. Lett. 27:149-154, 1985).

05728159 88153072 PMID: 2450068

Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin.

Tsuzuki K; Yokosawa N; Syuto B; Ohishi I; Fujii N ; Kimura K; Oguma K
Department of Microbiology, Sapporo Medical College, Japan.

Infection and immunity (UNITED STATES) Apr 1988 , 56 (4) p898-902,
ISSN 0019-9567 Journal Code: 0246127

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

The partial amino acid sequence of the light-chain (Lc) component of Clostridium botulinum type C1 toxin was determined. The sequence was quite similar to those of the other types of botulinum and tetanus toxins. Nine monoclonal antibodies against botulinum type E toxin were established by immunizing BALB/c mice with type E toxoid or its Lc component. Six antibodies reacted with the heavy-chain component and three reacted with the Lc component of the toxin. One of the latter three antibodies reacted with botulinum type B, C1, and D toxins and tetanus toxin, as well as botulinum type E toxin. This antibody recognized the Lc components of these toxins, indicating that there exists one common antigenic determinant on the Lc regions of these toxins.

Tags: Comparative Study; Support, Non-U.S. Gov't

Descriptors: *Antibodies, Monoclonal--immunology--IM; *Bacterial Toxins--immunology--IM; *Botulinum Toxins--immunology--IM; *Clostridium botulinum--immunology--IM; *Tetanus Toxin--immunology--IM; Amino Acid Sequence; Clostridium perfringens--immunology--IM; Epitopes; Immunosorbent Techniques ; Molecular Sequence Data

CAS Registry No.: 0 (Antibodies, Monoclonal); 0 (Bacterial Toxins); 0 (Botulinum Toxins); 0 (Epitopes); 0 (Tetanus Toxin)

Record Date Created: 19880419

Characterization of bacteriophage nucleic acids obtained from Clostridium botulinum types C and D.

Fujii N ; Oguma K ; Yokosawa N; Kimura K; Tsuzuki K

Department of Microbiology, Sapporo Medical College, Japan.

Applied and environmental microbiology (UNITED STATES) Jan 1988 , 54

(1) p69-73, ISSN 0099-2240 Journal Code: 7605801

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

Nontoxigenic strains of Clostridium botulinum types C and D are converted to toxigenic strains by infection with specific Tox+ bacteriophages. The nucleic acids were extracted from five converting phages, c-st, c-468, c-203, c-d6f, and d-1873, and one nonconverting phage, c-n71, and treated with nucleases. The nucleic acids isolated were not digested by RNase A, but were digested by DNase I and exonuclease III, indicating that they were double-stranded DNA. On the basis of the restriction endonuclease digestion patterns on 0.8% agarose gel electrophoresis, the length of c-st, c-n71, c-468, and c-d6f phage DNAs was estimated to be about 110 kilobase pairs and that of c-203 and d-1873 was about 150 kilobase pairs. The digestion patterns of c-st, c-468, and c-n71 phage DNAs by PstI and HindIII were very similar. High homology was observed in the dot hybridization test. For other phages and nucleases, a good similarity was not observed. Only a little similarity was observed between c-203 and c-d6f phages. The existence of the structural genes for the toxin in both c-st and c-n71 phages was confirmed by the hybridization test with these phage DNAs and the oligonucleotide probe which represented the DNA sequence predicted for the N-terminal amino acids (2 to 17) of C. botulinum type C toxin. The loss of the converting ability of c-n71 phage may be caused not by the deletion of the tox+ gene but rather by the base mutation in c-st phage DNA.

Tags: Support, Non-U.S. Gov't

Descriptors: *Bacteriophages--genetics--GE; *Clostridium botulinum --genetics--GE; *DNA, Viral--analysis--AN; Amino Acid Sequence; Botulinum Toxins--analysis--AN; Botulinum Toxins--genetics--GE; Molecular Sequence Data; Molecular Weight; Nucleic Acid Hybridization

CAS Registry No.: 0 (Botulinum Toxins); 0 (DNA, Viral)

Record Date Created: 19880404


?logoff hold

11 Functional Domains of Botulinal Neurotoxin.

12 Binding to cell surface. The carboxyl terminus of botulinal heavy chain is responsible for receptor binding on the cell surface. Initial work done using tetanus toxin, which is very similar in structure to botulinum neurotoxin, showed binding to cell receptors involved a multiple step binding sequence. The ten C-terminal amino acids are essential for initial receptor recognition on the motor neuron via a low affinity binding site while a sequence in the middle of the heavy chain was responsible for higher affinity secondary binding through a different protein receptor (Halpern, J. and Loftus, A., J. Biol. Chem. 268:11188-11192, 1993).

13 Evidence shows that binding by type B botulinum neurotoxin occurs in a similar fashion (Nishiki, T., et al., J. Biol. Chem. 269:10498-10503, 1994). The binding of type B neurotoxin to synaptosomes has been shown to be related to the presence of sialic acid containing motor neuron membrane components such as gangliosides G.sub.D1a and G.sub.T1b

as well as a partially purified 58 kD protein that has been tentatively determined to be synaptogamin. There is minimal binding of the neurotoxin to the 58 kD high affinity receptor in the absence of the low affinity gangliosides. This indicates that the initial low affinity binding to gangliosides which are prevalent on the cell surface by the carboxyl-terminal amino acids is followed by a high affinity binding to the 58 kD protein by an undetermined region that is more amino terminal possibly in the central portion of the heavy chain. Treatment of synaptosomes with proteases and or sialidase decreased binding of the neurotoxin to the synaptosomes.



EMBL-EBI

European Bioinformatics Institut

Get for Site search

[EBI Home](#)
[About EBI](#)
[Research](#)
[Services](#)
[Toolbox](#)
[Databases](#)
[Downloads](#)

ANALYSIS TOOLS

EBI

Generic DB Entry Retrieval

ID CBBONT standard; DNA; PRO; 4041 BP.
 XX
 AC M81186;
 XX
 SV M81186.1
 XX
 DT 28-MAY-1992 (Rel. 32, Created)
 DT 04-MAR-2000 (Rel. 63, Last updated, Version 4)
 XX
 DE Clostridium botulinum neurotoxin type B (botB) gene, complete cds.
 XX
 KW botB gene; neurotoxin type B.
 XX
 OS Clostridium botulinum
 OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;
 OC Clostridium.
 XX
 RN [1]
 RP 1-4041
 RA Whelan S.M., Elmore M.J., Bodsworth N.J., Brehm J.K., Atkinson T.,
 RA Minton N.P.;
 RT "Complete nucleotide sequence of the Clostridium botulinum gene encoding
 RT the type B neurotoxin";
 RL Unpublished.
 XX
 DR SWISS-PROT; P10844; BXB_CLOBO.
 XX
 FH Key Location/Qualifiers
 FH
 FT source 1..4041
 FT /db_xref="taxon:1491"
 FT /organism="Clostridium botulinum"
 FT CDS 57..3932
 FT /codon_start=1
 FT /db_xref="SWISS-PROT:P10844"
 FT /transl_table=11
 FT /function="vertebrate neurotoxin"
 FT /product="neurotoxin type B"
 FT /gene="botB"
 FT /protein_id="AAA23211.1"
 FT /translation="MPVTINNFFNYNDPIDNNNIIMMEPPFARGTGRIYKAFKITDRIWI
 FT IPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPL
 FT GEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGP
 FT GPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFS
 FT DPALILMHELIIHVLHGGLYGIKVDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIIT
 FT PSTDKSIYDKVLQNFGRGIVDRLNKLVCISDPNININIYKNKFKDKYKFVEDSEGGKYSI

```

FT      DVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFN
FT      ISDKDMEKEYRGQNKAINQAYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIA
FT      DKNSFSDDLKNERIEYNTQSNYIENDFPINELILDLDLISKIELPSENTESLTDNFVD
FT      VPVYEKQPAIKKIFTDENTIFQYLYSQTFFPLDIRDISLTSSFDALLFSNKVYSFFSMD
FT      YIKTANKVVEAGLFAGVWKQIVNDFVIEANKSNTMDKIADISLIVPYIGLALNVGNETA
FT      KGNFENAFEIAGASILFEFIPPELLIPVVGAFLLSEYIDNKNKI IKTIDNALTKRNEKWS
FT      DMYGLIVAQWLSTVNTQFYTIKEGMYKALNYQAQALEEIIKYRYNIYSEKEKSNINIDF
FT      NDINSKLNEGINQAINNINFINGCSVSYLMKKMIPLAVEKLLDFDNTLKKNLNLYIDE
FT      NKLYLIGSAEYEKSKVNKYLKTIMPFDLISIYTNDTILIEFMKNYSEILNNIILNLRYK
FT      DNNLIDLSGYGAKVEVDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSF
FT      WIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGNRIIWTLDINGKTKSVFFEY
FT      NIREDISSEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDI
FT      DRTQFIWMKYFSIFNTELSQSNIEERYKIQSYSEYKDFWGNPLMYNKEYYMFNAGNKN
FT      SYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDY
FT      IYLDFFNLNQEWVYTYKYFKKEEEKLFLAPISDSDEFYNTIQIKEYDEQPTYSCQLLF
FT      KKDEESTDEIGLIGHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIP
FT      KDEGWTE"
XX
SQ

```

Sequence 4041 BP; 1679 A; 383 C; 645 G; 1334 T; 0 other;

tgcgcattta	tgggcattaa	aagggatata	aacttaaaat	aaggaggaga	atattttatgc	60
cagttacaat	aaataatfff	aattataatg	atcctattga	taataataat	attattatga	120
tggagcctcc	atttgcgaga	ggtacgggga	gatattataa	agctttttaa	atcacagatc	180
gtatttggat	aataccggaa	agatatactt	ttggatataa	acctgaggat	tttaataaaa	240
gttccgggat	ttttaataga	gatgtttgtg	aataattatg	tccagattac	ttaaataacta	300
atgataaaaa	gaatatatff	ttacaaacaa	tgatcaagtt	atttaataga	atcaaatcaa	360
aaccattggg	tgaaaagtta	ttagagatga	ttataaatgg	tataccttat	cttggagata	420
gacgtgttcc	actcgaagag	tttaacacaa	acattgctag	tgtaactgtt	aataaaattaa	480
tcagtaatcc	aggagaagtg	gagcgaaaaa	aaggatffff	cgcaaatffa	ataatatttg	540
gacctggggc	agttttaaat	gaaaatgaga	ctatagatat	aggtatacaa	aatcattttg	600
catcaaggga	aggcttcggg	ggtataatgc	aaatgaagtt	ttgcccagaa	tatgtaagcg	660
tatttaataa	tgttcaagaa	aacaaaggcg	caagtatat	taatagacgt	ggatattttt	720
cagatccagc	cttgatatta	atgcatgaac	ttatacatgt	tttatcatga	ttatatggca	780
ttaaagtaga	tgattttacca	attgtaccaa	atgaaaaaaa	attttttatg	caatctacag	840
atgctataca	ggcagaagaa	ctatatacat	ttggaggaca	agatcccagc	atcataactc	900
cttctacgga	taaaagtatc	tatgataaag	ttttgcaaaa	tttttagaggg	atagttgata	960
gacttaacaa	ggttttagtt	tgcatatcag	atcctaacat	taatattaat	atatataaaa	1020
ataaatttaa	agataaatat	aaattcgttg	aagattctga	gggaaaatat	agtatagatg	1080
tagaaagttt	tgataaatta	tataaaagct	taatgtttgg	ttttacagaa	actaatatag	1140
cagaaaatta	taaaataaaa	actagagctt	cttatttttag	tgatttcctta	ccaccagtaa	1200
aaataaaaaa	tttattagat	aatgaaatct	atactataga	ggaagggttt	aatatatctg	1260
ataaagatat	ggaaaaagaa	tatagaggct	agaataaagc	tataaataaa	caagcttatg	1320
aagaaattag	caaggagcat	ttggctgtat	ataagataca	aatgtgtaaa	agtgttaag	1380
ctccaggaat	atgtattgat	gttgataatg	aagatttggt	ctttatagct	gataaaaaata	1440
gtttttcaga	tgattttatc	aaaaacgaaa	gaatagaata	taatacacag	agtaattata	1500
tagaaaatga	cttccttata	aatgaattaa	tttttagatac	tgatttaata	agtaaaatag	1560
aattaccaag	tgaaaataca	gaatcactta	ctgatttttaa	tgtagatggt	ccagtatatg	1620
aaaaacaacc	cgctataaaa	aaaatffffa	cagatgaaaa	taccatcttt	caatattttat	1680
actctcagac	atttctctta	gatataagag	atataagttt	aacatcttca	tttgatgatg	1740
cattattatt	ttctaacaaa	gtttattcat	ttttttctat	ggatttatatt	aaaactgcta	1800
ataaagtggg	agaagcagga	ttatttgtag	gttgggtgaa	acagatagta	aatgattttg	1860
taatcgagc	taataaaaagc	aatactatgg	ataaaattgc	agatatatct	ctaattgttc	1920
cttatatagg	attagcttta	aatgtaggaa	atgaaacagc	taaaggaaat	tttgaaaatg	1980
cttttgagat	tgcaggagcc	agtattctac	tagaattttat	accagaactt	tttaacctg	2040
tagttggagc	ctttttatta	gaatcatata	ttgacaataa	aaataaaatt	attaaaacaa	2100
tagataatgc	tttaactaaa	agaaatgaaa	aatggagtga	tatgtacgga	ttaatagtag	2160
cgcaatggct	ctcaacaggt	aatactcaat	tttatacaat	aaaagaggga	atgtataagg	2220
ctttaaatta	tcaagcacia	gcatttgaag	aaataataaa	atacagatat	aatatatatt	2280
ctgaaaaaga	aaagtcaaat	attaacatcg	attttaatga	tataaattct	aaacttaattg	2340
agggtattaa	ccaagctata	gataatataa	ataattttat	aaatggatgt	tctgtatcat	2400
atttaattgaa	aaaaatgatt	ccattagctg	tagaaaaatt	actagacttt	gataatactc	2460
tcaaaaaaaa	tttgttaaat	tatatagatg	aaaataaatt	atatttgatt	ggaagtgcag	2520
aatatgaaaa	atcaaaagta	aataaatact	tgaaaaccat	tatgccgttt	gatctttcaa	2580
tatatacca	tgatacaata	ctaatagaaa	tgtttaataa	atataatagc	gaaatttttaa	2640
ataatattat	cttaaatfta	agatataagg	ataataattt	aatagattta	tcaggatatg	2700
gggcaaagg	agaggtatat	gatggagtcg	agcttaattga	taaaaatcaa	tttaaatfta	2760

ctagttcagc aaatagtaag attagagtga ctcaaaatca gaatatcata tttaatagtg 2820
tgttccttga ttttagcgtt agcttttggg taagaatacc taaatataag aatgatggta 2880
tacaaaatta tattcataat gaatatacaa taattaattg tatgaaaaat aattcgggct 2940
ggaaaatcgc tattaggggt aataggataa tatggacttt aattgatata aatggaaaaa 3000
ccaaatcggg attttttggg tataacataa gagaagatat atcagagtat ataaatagat 3060
ggttttttgt aactattact aataatttga ataacgctaa aatttatatt aatggtaagc 3120
tagaatcaaa tacagatat aaagatataa gagaagtatt tgctaattgg gaaataatat 3180
ttaaattaga tgggtgatata gatagaacac aattttattg gatgaaatat ttcagtattt 3240
ttaatacgga attaagtcaa tcaaatttg aagaaagata taaaattcaa tcatatagcg 3300
aatattttaa agatttttgg ggaaatcctt taatgtacaa taaagaatat tatatgttta 3360
atgcggggaa taaaaattca tatattaaac taaagaaaga ttcacctgta ggtgaaattt 3420
taacacgtag caaatataat caaaattcta aatatataaa ttatagagat ttatatattg 3480
gagaaaaatt tattataaga agaaagtcaa attctcaatc tataaatgat gatatagtta 3540
gaaaagaaga ttatatatat ctagattttt ttaattttaa tcaagagtgg agagtatata 3600
cctataaata ttttaagaaa gaggaagaaa aattgtttt agtcctata agtgattctg 3660
atgagtttta caatactata caaataaaaag aatatgatga acagccaaca tatagttgtc 3720
agttgctttt taaaaaagat gaagaaagta ctgatgagat aggattgatt ggtattcatc 3780
gtttctacga atctggaatt gtatttgaag agtataaaga ttatttttgt ataagtaaat 3840
ggtacttaaa agaggtaaaa aggaaaccat ataattttaa attgggatgt aattggcagt 3900
ttattcctaa agatgaaggg tggactgaat aatataacta tatgctcagc aaacctattt 3960
tatataagaa aagtttaagt ttataaaatc ttaagtttaa ggatgtagct aaattttgaa 4020
tattagataa actacatgtt t 4041

//

Please contact support@ebi.ac.uk with any problems or suggestions regarding this site.

WEST Search History

DATE: Wednesday, October 30, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result s t
<i>DB=USPT; PLUR=YES; OP=AND</i>			
L1	heavy.clm. same chain.clm.	931	L1
L2	L1 and clostrid\$	16	L2
L3	L1 and botuli\$	12	L3
L4	(L3 or l2) and (coding or nucleic or nucleotide or dna or cdna or mrna or rna or genetic or chromosome or chromosomal or sequence or recombinant)	18	L4
L5	(4683195 4683202 4965188)! [pn]	3	L5
L6	(clostrid\$ or botuli\$ or neurotox\$ or bontoxyilysin\$ or \$endopeptidases or \$metalloproteinases or binary).ti,ab,clm.	33495	L6
L7	L6 and (heavy near5 chain)	89	L7
L8	L6 and (domain or carbox\$)	3091	L8
L9	L6 and (domain or domains or carboxy\$ or cterminal or c-terminal)	3125	L9
L10	L9 and (botx or botox or bnx or bottox or bot or serotype or sero-type of botulinum or botulism or btx or bont\$)	105	L10
L11	l1 same l6	9	L11
L12	(hchain or h-chain or hc or heavy) same (botulinum or botulism or botx or botox or bnx or bottox or bot or btx or bont or bont\$ or clostrid\$)	289	L12
	L12 same (vector or recombinant or mutation		

L13	or mutant or mutagenesis or dna or gene or genetic or coding or encoding or sequence or nucleic or nucleotide or nuclear or polynucleotide or dna or cdna or mrna or rna)	38	L13
L14	(urine or urina\$ or urinary).ti,ab,clm.	5642	L14
L15	L14 and (hcl or h-cl or acid\$ or hydrochlor\$) and (naoh or hydroxide or sodiumhydroxide or base or basic or neutral\$)	2429	L15
L16	L15 and (spin or precipit\$ or centrifug\$ or sediment\$)	1641	L16
L17	L16 and (top or supernatant or super-natant or separat\$ or remov\$ or decant\$)	1597	L17
L18	L17 and (dialysi\$ or filter or cutoff or cut-off or kda or kd or kilodalton or daltons or kilo-dalton or size or weight or exclusion)	1499	L18
L19	L18 and (tgfb or tgf\$ or transforming or growth or factor or beta or tgf-beta or tgfbeta)	1225	L19
L20	L18 and (tgfb or tgf\$ or transforming or growth or beta or tgf-beta or tgfbeta)	998	L20
L21	L18 and (tgfb or tgf\$ or transforming or beta or tgf-beta or tgfbeta)	742	L21
L22	L18 and (tgfb or tgf\$ or transforming or tgf-beta or tgfbeta)	139	L22
L23	L18 and (tgfb or tgf\$ or tgf-beta or tgfbeta)	38	L23
L24	acid\$ same (base\$ or neutral\$) same urin\$	1025	L24
L25	L24 same (centrifug\$ or spin\$ or precipit\$ or sediment\$)	108	L25
L26	L25 and (tgfb or tgf\$ or tgf-beta or tgfbeta)	17	L26
L27	('5883124' '5015571')[PN]	2	L27

L28	naoh.clm. and hcl.clm. and (urin\$.clm.	3	L28
L29	centrif\$.clm. and urin\$.clm.	69	L29
L30	L29 and (amicon or amikon or dializ\$ or dialysis)	18	L30

END OF SEARCH HISTORY

ID BXB_CLOBO_3; parent: BXB_CLOBO
FT CHAIN 441 1290 BOTULINUM NEUROTOXIN B, HEAVY-CHAIN.
SQ Sequence 850 AA;
APGICIDVDN EDLFFIADKN SFSDDLKNE RIEYNTQSNY IENDFPINEL ILDTDLISKI
ELPSENTESL TDFNVDVPVY EKQPAIKKIF TDENTIFOYL YSQTFFPLDIR DISLTSSFDD
ALLFSNKVYS FFSMDYIKTA NKVVEAGLFA GWVKQIVNDF VIEANKSNTM DKIAISLIV
PYIGLALNVG NETAKGNFEN AFEIAGASIL LEFIPELLIP VVGAFLLSEY IDNKNKIIKT
IDNALTKRNE KWSDMYGLIV AQWLSTVNTQ FYTIKEGMYK ALNYQAALE EIIKYRYNIY
SEKEKSNINI DFNDINSKLN EGINQAIDNI NNFINGCSVS YLMKKMIPLA VEKLLDFDNT
LKKNLLNYID ENKLYLIGSA EYEKSKVNKY LKTIMPFDSL IYTNDTILIE MFNKYNSEIL
NNIILNLRYK DNNLIDLSGY GAKVEVDGV ELNDKNQFKL TSSANSKIRV TQNQNIIFNS
~~VFLEDSWSFW TRIPKYNKDG IONYTHNEYT LINCCKNNSG WKISIRGNRI HWLLIDINGK~~
~~TKSVFFFEYNI REDISEYINR WFFVTITNNL NNAKIYINGK LESNTDIKDI REVIANGEII~~
~~EKLDGDIDRT QFIWMKYFSI FNTELSQSN I EERYKIQSYS EYLKDFWGNP LMYNKEYYMF~~
NAGNKNSYIK LKKDSPVGEI LTRSKYNQNS KYINYRDLYI GEKFIIRRS NSQSINDDIV
RKEDIYILDF FNLNQEWRY TYKYFKKEEE KLFLAPISDS DEFYNTIQIK EYDEQPTYSC
QLLFKKDEES TDEIGLIGIH RFYESGIVFE EYKDYFCISK WYLKEVKRKP YNLKLGCNWQ
FIPKDEGWTE

//

↑↑ mm↑↑
mm

General	Description	References	Comments	Links	Keywords	Features	Sequence
---------	--------------------	------------	----------	-------	----------	----------	----------

General information

Entry name	BXB_CLOBO
Accession number	<u>P10844</u> , <u>P10843</u>
Created	Rel. 11, 1-JUL-1989
Sequence update	Rel. 26, 1-JUL-1993
Annotation update	Rel. 41, 15-JUN-2002

Description and origin of the Protein

Description	Botulinum neurotoxin type B precursor (EC <u>3.4.24.69</u>) (BoNT/B) (Bontoxilysin B).
Gene name(s)	BOTB.
Organism source	Clostridium botulinum.
Taxonomy	Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae Clostridium.
NCBI TaxID	<u>1491</u>

References

	[1]	Whelan,S.M., Elmore,M.J., Bodsworth,N.J., Brehm,J.K., Atkinson,T., Minton,N.P., Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination o its entire nucleotide sequence. (1992) <i>Appl. Environ. Microbiol.</i> 58 :2345-2354	
		Position	SEQUENCE FROM N.A.
		Medline	<u>92384550</u>
		PubMed	<u>1514783</u>
	[2]	Szabo,E.A., Pemberton,J.M., Desmarchelier,P.M., Submitted	
		Position	SEQUENCE OF 35-245 FROM N.A.
		Comments	STRAIN=NCTC 7273;

- [3] Campbell,K., East,A.K., Collins,M.D.,
**Gene probes for identificati n of the botulinal neurotoxii
 gene and specific identification of neurotoxin types B, E
 and F.**

(1993) *J. Clin. Microbiol.* 31:2255-2262

Position SEQUENCE OF 633-993 FROM N.A.

Comments STRAIN=NCTC 7273;

Medline 94013372

PubMed 8408542

- [4] Dasgupta,B.R., Datta,A.,
**Botulinum neurotoxin type B (strain 657): partial sequenc
 and similarity with tetanus toxin.**

(1988) *Biochimie* 70:811-817

Position SEQUENCE OF 1-44 AND 441-466.

Comments STRAIN=657;

Medline 89000987

PubMed 3139097

- [5] Schmidt,J.J., Sathyamoorthy,V., Dasgupta,B.R.,
**Partial amino acid sequences of botulinum neurotoxins
 types B and E.**

(1985) *Arch. Biochem. Biophys.* 238:544-548

Position SEQUENCE OF 1-16 AND 441-458.

Comments STRAIN=OKRA;

Medline 85197963

PubMed 3888113

- [6] Schiavo,G., Rossetto,O., Santucci,A., Dasgupta,B.R.,
 Montecucco,C.,
Botulinum neurot xins are zinc proteins.

(1992) *J. Biol. Chem.* 267:23479-23483

Position IDENTIFICATION AS ZINC-PROTEASE

	Medline	<u>93054694</u>
	PubMed	<u>1429690</u>
[7]	<p>Schiavo,G., Benfenati,F., Poulain,B., Rossetto,O., de Laureto,P.P., Dasgupta,B.R., Montecucco,C., Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. (1992) <i>Nature</i> 359:832-835</p>	
	Position	IDENTIFICATION OF SUBSTRATE.
	Medline	<u>93063293</u>
	PubMed	<u>1331807</u>

Comments

FUNCTION

BOTULINUS TOXIN ACTS BY INHIBITING NEUROTRANSMITTER RELEASE. IT BINDS TO PERIPHERAL NEURONAL SYNAPSES, IS INTERNALIZED AND MOVES BY RETROGRADE TRANSPORT UP THE AXON INTO THE SPINAL CORD WHERE IT CAN MOVE BETWEEN POSTSYNAPTIC AND PRESYNAPTIC NEURONS. IT INHIBITS NEUROTRANSMITTER RELEASE BY ACTING AS A ZINC ENDOPEPTIDASE THAT CLEAVES THE 76-GLN-|-PHE-77 BOND OF SYNAPTOBREVIN-2.

CATALYTIC ACTIVITY

LIMITED HYDROLYSIS OF PROTEINS OF THE NEUROEXOCYTOSIS APPARATUS, SYNAPTOBREVINS, SNAP25 OR SYNTAXIN. NO DETECTED ACTION ON SMALL MOLECULE SUBSTRATES.

COFACTOR	BINDS 1 ZINC ION PER SUBUNIT (BY SIMILARITY).
SUBUNIT	DISULFIDE-LINKED HETERODIMER OF A LIGHT CHAIN (L) AND A HEAVY CHAIN (H). THE LIGHT CHAIN HAS TH PHARMACOLOGICAL ACTIVITY, WHILE THE N-AND C-TERMINAL OF THE HEAVY CHAIN MEDIATE CHANNEL FORMATION AND TOXIN BINDING, RESPECTIVELY.
SUBCELLULAR LOCATION	SECRETED.
MISCELLANEOUS	THERE ARE SEVEN ANTIGENICALLY DISTINCT FORMS OF BOTULINUM NEUROTOXIN: TYPES A, B, C1, D, E, F, AND G.
SIMILARITY	BELONGS TO PEPTIDASE FAMILY M27

Copyright

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

Database cross-references


EMBL	<u>M81186;AAA23211.1;-.</u>
	<u>Z11934;CAA77991.1;-.</u>
	<u>X70817;CAA50148.1;-.</u>
	S07128;S07128.
	S07155;S07155.

PIR	S08562;S08562. S08573;S08573. S08574;S08574. A48940;A48940.
HSSP	P10845; <u>3BTA</u> .
MEROPS	<u>M27.002</u> ;.-.
InterPro	<u>IPR000395</u> ;Bontoxilysin. <u>IPR000130</u> ;Zn_MTpeptdse.
Pfam	<u>PF01742</u> ;Peptidase_M27;1.
PRINTS	<u>PR00760</u> ;BONTOXILYSIN.
ProDom	<u>PD001963</u> ;Bontoxilysin;1.
PROSITE	<u>PS00142</u> ;ZINC_PROTEASE;1.

Keywords

Neurotoxin; Transmembrane; Hydrolase; Metalloprotease; Zinc;

Features



Key	Begin	End	Length	Description
<u>INIT MET</u>	0	0	1	
<u>CHAIN</u>	1	440	440	BOTULINUM NEUROTOXIN B, LIGHT-CHAIN.
<u>CHAIN</u>	441	1290	850	BOTULINUM NEUROTOXIN B, HEAVY-CHAIN.
<u>METAL</u>	229	229	1	ZINC (CATALYTIC) (BY SIMILARITY).
<u>ACT SITE</u>	230	230	1	BY SIMILARITY.
<u>METAL</u>	233	233	1	ZINC (CATALYTIC) (BY SIMILARITY).
<u>DISULFID</u>	436	445	10	INTERCHAIN (PROBABLE).
<u>CONFLICT</u>	29	29	1	T -> M (IN REF. 4).
<u>CONFLICT</u>	217	217	1	R -> G (IN REF. 2).
<u>CONFLICT</u>	224	224	1	A -> S (IN REF. 2).
<u>CONFLICT</u>	463	463	1	S -> R (IN REF. 4).

10/31/02
10/02
Searches
BP

Sequence information

Length: 1290 aa, molecular weight: 150670 Da, CRC64 checksum:
D21746E2C024DF43

```

PVTINNFNYN DPIDNNNIIM MEPPFARGTG RYYKAFKITD RIWIIPERYT FGYPKPEDFNK      60
SSGIFNRDVC EYYDPDYLNT NDKKNIFLQT MIKLFNRIKS KPLGEKLLEM IINGIPYLGD      120
RRVPLEEFNT NIASVTVNKL ISNPGEVERK KGIFANLIIF GPGPVLNENE TIDIGIQNHF      180
ASREGFGGIM QMKFCPEYVS VFNNVQENKG ASIFNRRGYF SDPALILMHE LIHVLHGLYG      240
IKVDDLPIPV NEKKFFMQST DAIQAEELYT FGGQDPSIIT PSTDKSIYDK VLQNFGRIVD      300
RLNKVLVCIS DPNININIYK NKFKDKYKFV EDSEGKYSID VESFDKLYKS LMFQFTETNI      360
AENYKIKTRA SYFSDSLPPV KIKNLLDNEI YTIEEGFNIS DKDMEKEYRG QNKAINKQAY      420
EEISKEHLAV YKIQMCKSVK APGICIDVDN EDLFFIADKN SFSDDLKNE RIEYNTQSNY      480
IENDFPINEL ILDTDLISKI ELPSENTESL TDFNVDPVYV EKQPAIKKIF TDENTIFQYL      540
YSQTFPLDIR DISLTSSFDD ALLFSNKVYS FFSMDYIKTA NKVVEAGLFA GWVKQIVNDF      600
VIEANKSNTM DKIAISLIV PYIGLALNVG NETAKGNFEN AFEIAGASIL LEFIPELLIP      660
VVGAFLLSEY IDNKNKIIKT IDNALTKRNE KWSDMYGLIV AQWLSTVNTQ FYTIKEGMYK      720
ALNYQAQALE EIIKYRYNIY SEKEKSNINI DFNDINSKLN EGINQAIDNI NNFINGCSVS      780
YLMKKMIPLA VEKLLDFDNT LKKNLLNYID ENKLYLIGSA EYEKSKVNKY LKTIMPFDL      840
IYTNDTILIE MFNKYNSEIL NNIIILNRYK DNNLIDLSGY GAKVEVDGV ELNDKNQFKL      900
TSSANSKIRV TQNQNIIFNS VFLDFSVSFW IRIPKYKNDG IQNYIHNEYT IINCMKNNSG      960
WKISIRGNRI IWTLIDINGK TKSVPFEYNI REDISEYINR WFFVTITNNL NNAKIYINGK     1020
LESNTDIKDI REVIANGEII FKLDGDIDRT QFIWMKYFSI FNTELSQSN I EERYKIQSYS     1080
EYLKDFWGNP LMYNKEYYMF NAGNKNSYIK LKKDSPVGEI LTRSKYNQNS KYINYRDLYI     1140
GEKFIIIRKS NSQSINDDIV RKEDYIYLD FNLNQEW RVY TYKYFKKEEE KLFLAPISDS     1200
DEFYNTIQIK EYDEQPTYSC QLLFKKDEES TDEIGLIGIH RFYESGIVFE EYKDYFCISK     1260
WYLKEVKRKP YNLKLGCNWQ FIPKDEGWTE                                     1290

```

//

General	Description	References	Comments	Links	Keywords	Features	Sequence
-------------------------	-----------------------------	----------------------------	--------------------------	-----------------------	--------------------------	--------------------------	--------------------------